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                                                   ABBREVIATIONS 
 
BBB                                           blood - brain barrier                             
BGT-1                                       betaine/GABA transporter 
BSA                                           bovine serum albumin 
CA                                             cornu amonis 
CA1                                           hippocampus CA1 area 
CA3                                           hippocampus CA3 area 
CAT                                          chloramphenicol acetyltransferase 
CNS                                           central nervous system 
CPM                                          count per minute 
DAB                                          3, 3 - diaminobenzidine   tetrahydrochloride 
DNA                                          deoxyribonucleic acid 
EDTA                                        ethylenediaminetetraacetic acid 
ELISA                                        enzyme linked immunosorbent assay 
EMSA                                        electrophoretic mobility shift assay 
GABA                                        γ-aminobutyric acid 
GABA - T                                  GABA transaminase 
GAD                                          glutamic acid decarboxylase 
GAT                                           GABA transport 
GFAP                                         glial fibrillary acidic protein 
GS                                               glutamine synthetase 
[3H]GABA                                  tritium labelled GABA 
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IC50                                             concentration at 50% inhibition       
KA                                              kainic acid 
Km                                             Michaelis constant 
MDCK                                        Madin-Darby canine kidney 
MW                                             molecular weight 
NMR                                           nuclear magnetic resonance 
OsO4                                           osmium tetroxide 
PB                                               phosphate buffer 
PBS                                             phosphate-buffered saline 
PCR                                             polymerase chain reaction 
PKA                                            protein kinase A  
PKC                                             protein kinase C 
RNA                                            ribonucleic acid 
RT - PCR                                     reverse transcription polymerase chain reaction 
TauT                                            taurine transporter 
TCA                                             tricarboxylic acid 
TonE                                            tonicity-responsive enhancer  







       Osmoregulation is critical for maintaining brain function. In response to 
hyperosmotic stress, brain cells, including neurons and glial cells can accumulate 
organic osmolyte: betaine, myo-inositol and taurine via the osmolyte transport. The 
betaine/GABA transporter BGT-1 has been extensively studied in MDCK cells, and 
it is responsible for the uptake of betaine into kidney cells when adapted to 
hyperosmotic environment. However, the localization and function of BGT-1 in the 
brain has been unclear. Although BGT-1 mRNA is widely expressed in the brain, 
previous studies on distribution of BGT-1 in the brain are only carried out at mRNA 
level using Northern blot and in-situ hybridization. The distribution and subcellular 
location of BGT-1 has to be addressed at protein level, in order to gain a thorough 
understanding of its function in the brain. BGT-1 is capable of transporting both 
betaine and GABA, as examined in Xenopus oocytes and various cell lines. But the 
physiological substrate of BGT-1 in the brain remains to be determined. Of 
particular interest is the elucidation of the role of BGT-1 in excitotoxic brain injury, 
since under such circumstances of neuronal injury, osmotic stress resulted to certain 
extent from the release of neuronal content, including the highly abundant betaine, 
as well as the altered levels of extracellular GABA, could be related to the function 
of BGT-1.  
        The present study first addressed the question of what is the normal distribution 
and subcellular location of BGT-1 in the brain. The use of a specific antibody to 
BGT-1 detected the presence of BGT-1 in the cell bodies and dendrites of pyramidal 
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neurons in the cerebral neocortex and CA fields of hippocampus. Electron 
microscopy reveals that BGT-1 is postsynaptically localized in asymmetric synapse. 
The distribution of BGT-1 on dendritic spines, rather than at GABAergic axon 
terminals, suggests that the transporter is unlikely to play a major role in terminating 
the action of GABA at a synapse. Instead, the osmolyte betaine is more likely to be 
the physiological substrate of BGT-1 in the brain, and the presence of BGT-1 in 
pyramidal neurons suggests that these neurons utilize betaine to maintain osmolarity. 
         Meanwhile, the present study explored the changes in the expression of GABA 
transporters in the rat hippocampus after kainate-induced neuronal injury, since 
changes in expression of GABA transporters/BGT-1 might result in alterations in 
levels of GABA/betaine in the extracellular space, with consequent effects on 
neuronal excitability or osmolarity. A decrease in GAT-1 and GAT-3 
immunostaining, but no change in GAT-2 staining, was observed in the degenerating 
CA subfields. In contrast, increased BGT-1 immunoreactivity was observed in 
astrocytes after kainate injection. BGT-1 is a weak transporter of GABA as 
compared to other GABA transporters, and the increased expression of BGT-1 in 
astrocytes might be a protective mechanism against increased osmotic stress known 
to occur after excitotoxic injury. On the other hand, excessive or prolonged BGT-1 
expression might be a factor contributing to astrocytic swelling after brain injury. 
       It is conceivable that BGT-1 could have been induced in astrocytes as a result of 
induction by betaine or hyperosmotic stress after excitotoxic injury. Finally, the 
present study investigated the possible changes in betaine transporter expression and 
its function in astrocytes, after treatment with high concentrations of betaine or 
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sucrose in vitro, as well as the effect of betaine on its transporter BGT-1 in reactive 
astrocytes in vivo. Treatment of human U373 MG astrocytoma cells for 12 hours 
with 1-100 mM of betaine, but not equivalent concentrations of sucrose, resulted in 
increased BGT-1 immunointensity by ELISA. The increased BGT-1 was present in 
the cytoplasm and cell membrane. Treatment of cells with 1-100 mM betaine also 
resulted in increased [14C] betaine transport into the cells, consistent with increased 
BGT-1 transporter function. No increase in betaine uptake was observed when cells 
were treated with 1 and 10 mM sucrose, but a large increase was observed when 
cells were treated with 100 mM sucrose. In contrast to rats received 
intracerebroventricular injection with kainate plus saline, which showed loss of 
BGT-1 immunoreactivity in neurons and little induction of BGT-1 in astrocytes, a 
marked increase in BGT-1 immunoreactivity was observed in astrocytes in the 
degenerating CA fields and fimbria, in rats injected with kainate plus betaine. These 
astrocytes were found to have swollen mitochondria at electron microscopy. In view 
of the above findings, it is postulated that the release of betaine from dying neurons 
could be a factor contributing to increase BGT-1 expression in astrocytes. This 
might contribute to astrocytic swelling following head injury or stroke.    
        In summary, the present study has revealed the distribution of betaine/GABA 
transporter BGT-1 in normal brain and in excitotoxic brain injury, as well as the 
expression and functional changes of BGT-1 in astrocytes in response to 
hyperosmolarity in vitro and in vivo. Overall, the present study has dissected the role 
of BGT-1 in osmoregulation in the brain. Further studies are necessary to study the 
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mechanism by which betaine induces BGT-1 expression and the effects of BGT-1 
















1. Maintenance of osmolarity in living cells 
       Maintenance of osmotic balance is an important aspect of cellular homeostasis. 
When exposed to extracellular hyperosmolarity, cells initially lose water and shrink, 
thus concentrating intracellular inorganic ions. Accumulation of inorganic ions (e.g., 
sodium and potassium salts) and crowding of large intracellular molecules have been 
demonstrated to compromise the function of proteins, DNA and other cellular 
macromolecules (Yancey et al., 1982; Minton, 1983; Garner and Burg, 1994). Upon 
the prolonged hyperosmotic challenge, virtually all cells from bacterial to 
mammalian slowly accumulate certain small organic solutes, e.g., betaine, taurine 
and myo-inositol, to achieve osmotic balance. Compared to the high concentrations 
of intracellular inorganic ions, these small organic solutes generally do not perturb 
the function of macromolecules, so termed compatible (or non-purturbing) 
osmolytes (Yancey et al., 1982). Accumulation of specific osmolytes results from 
their intracellular synthesis or uptake from extracellular space via the corresponding 
osmolyte transporters (Burg, 1995). On the other hand, adaptation of cells to 
hypoosmotic condition requires the release of intracellular osmolytes (Kwon and 
Handler, 1995). 
       Since cell membrane is highly permeable to water, disturbance in 
osmoregulation would directly affect the cell volume, thus interfering with a 





1.1. Maintenance of osmolarity in the kidney 
        Maintenance of osmolarity is essential for the physiological functioning of 
kidney cells. The renal medulla is the site of final urine formation. The 
hyperosmolarity in renal medulla provides the driving force for extraction of water 
from the urine, thus concentrating urine. Osmolarity of the renal medulla can be 
easily raised to over 1000 mosM in humans and over 3000 mosM in rats (Garcia-
Perez and Burg, 1991; Sone et al., 1995). To balance the high extracellular 
osmolarity, cells in the inner renal medulla accumulate large amounts of certain 
osmolytes, predominantly sorbitol, myo-inositol, betaine and taurine (Burg et al., 
1997). These organic osmolytes help to protect the cells against hyperosmolarity. 
Therefore, physiological functioning of the kidney depends critically on the ability 
of the renal medullary cells to adapt to the hyperosmolarity. 
 
1.2. Maintenance of osmolarity in the central nervous system 
       Osmoregulation plays a critical role in the brain, where changes in cell volume 
can not be tolerated due to the rigid, non-expandable skull and where alterations in 
ion composition would affect excitability (Strange, 1992; Gullans and Verbalis, 
1993; Law, 1994a; Lang et al., 1998).  
       Hypernatremia and hyponatremia are very common clinical problems. 
Hyperosmolarity as a result of hypernatremic state leads to the cellular dehydration 
due to water movement from the intracellular space to the hyperosmotic 
extracellular space. In response to hyperosmolarity, brain cells subsequently 
accumulate osmolytes to restore to the normal volume level. Exposure of cultured 
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brain cells to hyperosmolarity shows a significant increase in the content of organic 
osmolyte (Strange et al., 1991; Beetsch and Olson, 1996). Studies of hypernatremic 
animals indicate that the organic osmolyte accumulation generally accounts for 30-
50% of the total osmolyte accumulation (Chan and Fishman, 1979; Heilig et al., 
1989; Lien et al., 1990). When hypernatremic state persists and exceeds the brain’s 
ability to compensate for cellular dehydration, such neurological symptoms as 
irritability, stupor, hyperreflexia and coma would develop (Arieff, 1984; Gullans and 
Verbalis, 1993). 
       It is well documented that hyponatremia causes brain edema as a consequence 
of influx of water into brain. Due to increased intracranial pressure, brain edema 
leads to life-threatening cessation of the brain’s blood supply and neuronal death 
(Kimelberg, 1995; Pasantes-Morales et al., 2002). To adapt to hypoosmolarity, brain 
cells exclude intracellular osmolytes, mainly the inorganic ions potassium (K+) and 
chloride (Cl-) and a number of organic osmolytes. Release of organic osmolytes has 
been shown to contribute significantly to the adaptive response to hyponatremia 
(Lien et al., 1991; Verbalis and Gullans, 1991; Sterns et al., 1993). In vitro studies in 
both neurons and astrocytes also demonstrate the persistent exclusion of organic 
osmolytes, e.g., taurine following hypoosmotic stimulus (Pasantes and Schousboe, 
1988; Schousboe et al., 1991; Olson, 1999). 
      In addition, osmotic stress directly influences neuronal electrophysiological 
function. Alteration in ion concentrations in extracellular as well as intracellular 
spaces would affect membrane potential and the resulting neuronal excitability. 
Neuronal excitability increases significantly in hippocampal slices under 
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hypoosmotic conditions (Chebabo et al., 1995). The hypoosmotic-associated 
hyperexcitability has been shown in patients of hyponatremia with an increased 
susceptibility to seizures (Andrew, 1991). In vitro studies in brain slices reveal that 
osmolarity reduction enhances the synaptic transmission whilst raising osmolarity 
depresses synapses (Rosen and Andrew, 1990; Chebabo et al., 1995; Huang et al., 
1997). When confronted with hyperosmolarity, neurons of primary culture show 
enhanced voltage-dependent Ca2+ currents and depressed K+ currents (Somjen, 
1999). 
 
2. Organic osmolytes 
       The different organic osmolytes that are accumulated by cells fall into three 
classes: methylamines, such as betaine and glycerophosphorylcholine; polyalcohols, 
such as myo-inositol and sorbitol; and amino acids or amino acid derivatives, such 
as glycine and taurine (Lang et al., 1998). The followings highlight some major 
osmolytes in the brain. 
 
2.1. Betaine 
        Betaine (N, N, N-trimethylglycine) has been shown an osmoprotective role in 
many plant, animal and bacterial species (Yancey et al., 1982; Le Rudulier and 
Bouillard, 1983; Perroud and Le Rudulier, 1985; Bagnasco et al., 1986; Yancey and 
Burg, 1990). It is well documented that the kidney medulla becomes hyperosmotic 
when concentrating urea and large amounts of betaine is intracellularly accumulated 
(Bagnasco et al., 1986; Balaban and Burg, 1987; Garcia-Perez and Burg, 1991).  
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        In addition to the uptake from the extracellular environment through transporter, 
betaine can be synthesized in vivo from its precursor, choline. Production of betaine 
by oxidation of choline has been reported in gut mucosa (Flower et al., 1972), liver 
(Glenn and Vanko, 1959; Wilken et al., 1970), and kidney (Haubrich et al., 1975). 
Fig 1 illustrates the metabolic pathway for betaine synthesis and degradation. 
Betaine is synthesized via two oxidative steps. Choline is oxidized by choline 
dehydrogenase (EC 1.1.99.1) to betaine aldehyde, which is further oxidized to 
betaine by betaine aldehyde dehydrogenase (EC 1.2.1.8) (Rothschild and Barron, 
1954). Choline dehydrogenase itself may also be able to catalyze both steps (Tsuge 
et al., 1980).  
        Betaine degradation is catalyzed by betaine homocysteine methyltransferase 
(EC 2.1.1.5) (Skiba et al., 1987). In this reaction, a methyl group is transferred from 
betaine to homocysteine to form methionine. After donating its methyl group, 
betaine becomes dimethylglycine. It has been well-documented that in liver, betaine 
acts as a methyl donor in the detoxification of homocysteine (Gaitonde, 1970; 
Finkelstein et al., 1982). Clinically, betaine is used for treatment of homocystinuria, 
which caused by a genetic defect in cystathione β-synthase (an enzyme in the trans-
sulfuration pathway of homocysteine metabolism) (Smolin et al., 1981; Wilcken and 
Wilcken, 1997; Walter et al., 1998). 
      Within the kidney, the production of betaine from choline occurs in proximal 
tubule (Wirthensohn and Guder, 1982; Miller et al., 1996) and renal medullary cells 
(Grossman and Hebert, 1989; Lohr and Acara, 1990), both of which contain choline 
dehydrogenase activity. It raises the possibility that alterations of betaine synthesis 
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in the renal medulla may contribute to its osmotic regulation. However, no evidence 
favors this. Hypernatremia, which results in major accumulation of betaine in renal 
medullas, does not show an increase in the activity of choline dehydrogenase 
(Grossman and Hebert, 1989). MDCK (Madin-Darby canine kidney) cells, which 
accumulate betaine when grown in hyperosmotic media, have little capacity to 
synthesize betaine and rely on uptake from the medium (Nakanishi et al., 1990). 
Thus, the role of betaine synthesis in osmoregulation is not well supported. 
       In contrast, betaine metabolism is poorly characterized in the central nervous 
system (CNS), although betaine has been detected in rat brain (Heilig et al., 1989; 
Lien et al., 1990; Lien, 1995; Koc et al., 2002). No information on betaine synthesis 
in CNS has been reported. The activity of betaine homocysteine methyltransferase, 
the enzyme responsible for betaine degradation, is absent in brain (McKeever et al., 
1991). It is likely that betaine synthesized elsewhere, e.g. liver, kidney, is 
transported into the brain via blood-brain barrier (BBB), since betaine/GABA 
transporter BGT-1 is localized in BBB (Takanaga et al., 2001). High concentrations 
of betaine (100-300 mM) have been found in single neurons isolated from the 
abdominal ganglion from Aplysia Californica using nuclear magnetic resonance 
(NMR) spectroscopy. The levels of betaine in brain are increased following salt 
loading, suggesting a role of betaine in osmoregulation in the CNS (Lien et al., 
1990). It is noteworthy that cerebral edema was clinically reported in patients treated 





         Taurine (2-aminoethanesulfonic acid) is widely distributed in the brain, and its 
intracellular concentration can reach tens of milliMolar (Palkovits et al., 1986; 
Huxtable, 1989). The highest levels of taurine are present in cerebral cortex, 
hippocampus, caudate-putamen, cerebellum and hypothalamic supraoptic nuclei, 
while lower levels are found in the brain stem (Palkovits et al., 1986). Taurine has 
been detected in neurons, e.g., cerebellar Purkinje neurons, neurons of cortex and 
hippocampus, as well as in glial cells (Hussy et al., 2000). The biosynthesis of 
taurine is primarily from cysteine derived in part from methionine via the cysteine 
sulfinate pathway, which includes oxidation of cysteine to cysteine sulfinate by 
cysteine dioxygenase and decarboxylation of cysteine sulfinate by cysteine sulfinate 
decarboxylase (Foos and Wu, 2002; Tappaz, 2004). 
        The role of taurine in osmoregulation in the brain has been well established. 
Efflux of taurine in response to osmotic reduction has been consistently shown in 
numerous preparations of in vitro studies, including neurons (Schousboe et al., 1991; 
Pasantes-Morales et al., 1994), astrocytes (Pasantes and Schousboe, 1988; 
Kimelberg et al., 1990; Vitarella et al., 1994), and brain slices (Oja and Saransaari, 
1992; Law, 1994b). In vivo studies on hyponatremia confirm a decreased level of 
taurine in brain (Thurston et al., 1987; Verbalis and Gullans, 1991; Lien et al., 1991). 
On the other hand, intracellular accumulation of taurine as a result of hyperosmotic 
stimulus has been demonstrated in cultured astrocytes (Olson and Goldfinger, 1990; 
Sanchez-Olea et al., 1992), as well as in vivo studies (Thurston et al., 1980; Lien et 
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al., 1990). In addition, taurine-deficient astrocytes in culture show impaired volume 
regulation (Moran et al., 1994). 
         Besides biosynthesis, taurine transport significantly contributes to maintenance 
of high intracellular levels of taurine in the brain (Sanchez-Olea et al., 1992; Bitoun 
and Tappaz, 2000a; Bitoun and Tappaz, 2000b). In addition to osmoregulation, 
taurine has been assigned various roles in the brain, e.g., neuroprotection against 
neurotoxicity (Saransaari and Oja, 2000), and modulation of intracellular calcium 
homeostasis (Foos and Wu, 2002). 
 
2.3. Myo-inositol  
       Myo-inositol is richly present in the brain with heterogenous distribution (2-15 
mM) (Fisher et al., 2002). Myo-inositol serves as an osmolyte, such as by 
accumulation upon extracellular hyperosmolarity and exclusion in response to 
osmotic reduction, has been shown in numerous studies in the brain, both in vitro 
and in vivo preparations (Lien et al., 1990; Strange et al., 1991; Verbalis and Gullans, 
1991; Paredes et al., 1992; Strange and Morrison, 1992; Strange et al., 1993; Isaacks 
et al., 1994). Uptake by myo-inositol transporter as well as de novo biosynthesis 
from D-glucose-6-phosphate plays an important role in maintaining myo-inositol 






3. Osmolyte transporters 
3.1. Betaine/GABA transporter BGT-1 
3.1.1. Cloning of BGT-1 
        Betaine, as a protective osmolyte has been shown in many plant, animal and 
bacterial species (Yancey et al., 1982; Le Rudulier and Bouillard, 1983; Perroud and 
Le Rudulier, 1985; Bagnasco et al., 1986; Yancey and Burg, 1990). Escherichia coli 
and Salmonella typhimurium utilize a high-affinity betaine transporter encoded by 
proU gene to accumulate betaine under hyperosmotic stress (Barron et al., 1987; 
Stirling et al., 1989). It has been recognized that large amounts of betaine is 
intracellularly accumulated in the kidney medulla (Bagnasco et al., 1986; Balaban 
and Burg, 1987; Garcia-Perez and Burg, 1991). 
         In studies on the accumulation of betaine and its transporter, Madin-Darby 
canine kidney (MDCK) cells have proved to be a valuable model system. A series of 
elegant experiments on MDCK cells have led to the cloning and characterization of 
the betaine/GABA transporter BGT-1 and subsequent elucidation of detailed 
mechanisms regarding the role of BGT-1 in osmoregulation in kidney cells. MDCK 
cells have shown to accumulate betaine when grown in hyperosmotic media 
(Nakanishi et al., 1988). Further studies revealed that the intracellular accumulation 
of betaine is due to increased Na+-dependent uptake from the culture medium 
(Nakanishi et al., 1990). When MDCK cells were cultured at normal osmolarity in a 
defined betaine-free medium, no betaine was detected in the cells. After changing to 
a medium made hyperosmotic to 500 mosmol/kg H2O by adding NaCl and 
containing 50 µM betaine, the level of intracellular betaine increased and lasted over 
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1 week. If the culture medium contained no betaine, the cells did not accumulate 
betaine even at the higher osmolarity. Additional kinetic analysis showed that under 
hyperosmotic media, the maximal velocity (Vmax) of Na+-dependent betaine uptake 
increases with no apparent change in Km, suggesting that extracellular 
hyperosmolarity induces an increase in the number of functional betaine transporter 
in the plasma membrane (Nakanishi et al., 1990). With the technological mature of 
heterologus expression in Xenopus oocyte, a variety of Na+-dependent membrane 
transporters encoded by exogenous mRNA have been successfully expressed in 
Xenopus oocyte during the late 1980s (Hediger et al., 1987; Aoshima et al., 1988; 
Longoni et al., 1988; Sigel et al., 1988; Hagenbuch et al., 1990). Similarly, this 
technology was employed to express the mRNA from MDCK cells and assay the 
betaine uptake in Xenopus oocyte (Robey et al., 1991). The results are quite 
inspiring. Injection of mRNA from hyperosmotic MDCK cells into Xenopus oocyte 
induces significantly increased betaine uptake, compared to the mRNA from 
isosmotic MDCK cells. The greatest betaine uptake activity results from an mRNA 
fraction with a median size of approximately 2.8 kilobases.  The above 
achievements pave the way for the successful cloning of the betaine/GABA 
transporter BGT-1 since neither the related sequence information nor the antibody to 
the transporter were available at that time. 
         Further efforts brought about the cloning of the betaine/GABA transporter 
cDNA from MDCK cells using the above mentioned heterologus expression in 
Xenopus oocyte to screen a cDNA library (Yamauchi et al., 1992). Interestingly, the 
cloned transporter is capable of utilizing both betaine and GABA, a principle 
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inhibitory neurotransmitter, as substrates; hence named BGT-1. It is worth to note 
that the first GABA transport GAT-1 has been previously cloned from rat brain 
(Guastella et al., 1990). The deduced amino acid sequence of BGT-1 exhibits highly 
significant sequence and topographic similarity to the rat brain GAT-1, suggesting 
that the kidney BGT-1 and brain GAT-1 are members of the same transporter gene 
family. Shortly after its identification in MDCK cells, BGT-1 was also cloned from 
the mouse brain (originally named mouse GAT-2) (Lopez-Corcuera et al., 1992), 
and subsequently from human kidney (Rasola et al., 1995), human brain (Borden et 
al., 1995b), rat liver (Burnham et al., 1996)  and  rabbit renal papilla cells (Ferraris et 
al., 1996). 
 
3.1.2. Molecular structure of BGT-1 
         The entire BGT-1 gene from MDCK cells has been cloned and analyzed. It 
extends over 28 kilobases and consists of 18 exons. Three alternative first exons in 
the 5' end of the gene, together with alternative splicing, produces a complex 
mixture of mRNAs. Eight kinds of BGT-1 mRNA (classified into three types 
according to the 5' end sequence) have been identified. They diverge in their 5’-
untranslated region and have the identical open reading frame. Each type of mRNA 
is expressed in a tissue - specific manner. Type A is found only in kidney medulla, 
while type B is present in brain, liver, kidney cortex and medulla, type C in brain, 
kidney cortex and medulla. Use of Northern blot analysis reveals that 
hyperosmolarity induces all three type mRNAs in MDCK cells. Primer extension 
and/or RNase protection assays as well as transfection assays into MDCK cells 
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demonstrate that the three alternative first exons each have an independent 
transcription initiation site controlled under an independent promoter (Takenaka et 
al., 1995). 
       The deduced amino acid sequence of canine BGT-1 reveals a single protein of 
614 amino acids with 12 putative membrane-spanning domains. In addition, it 
contains several potential phosphorylation sites for protein kinase A and C, and two 
potential glycosylation sites, suggesting possible posttranslational regulation. Both 
N- and C-terminal domains containing potential phosphorylation sites are predicted 
to be located at the intracellular side of the transporter (Yamauchi et al., 1992). 
       The transporter BGT-1 cloned from human brain displays 91% amino acid 
identity with canine BGT-1 (Borden et al., 1995b), and the mouse brain BGT-1 
(originally named mouse GAT-2) displays 88% amino acid identity with canine 
BGT-1 (Lopez-Corcuera et al., 1992). All of these share the similar hydropathy plot 
with a single protein of 614 amino acids. Despite their high overall amino acid 
identities, alignment of BGT-1 sequences from the human brain, mouse brain and 
MDCK cell reveals the differences in the number and location of potential 
phosphorylation sites (Borden et al., 1995b).  
 
3.1.3. Distribution of BGT-1 
         The canine BGT-1 is present on the basolateral surface of MDCK cells 
(Yamauchi et al., 1991). Use of Northern Blot and in situ hybridization reveals a 
widespread distribution of BGT-1 mRNA that does not closely match the 
GABAergic pathways in the human and mouse brain, suggesting that BGT-1 might 
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not play a role in terminating the action of GABA at the synapse (Borden et al., 
1995b). 
        Pietrini et al. utilized monolayer cultures of MDCK cells as a model system for 
the study of membrane protein sorting in neurons and found that BGT-1 was 
localized to the basolateral membrane, suggesting a dendritic localization in neurons 
(Pietrini et al., 1994).  
 
3.1.4. Functional characterization of BGT-1 
         BGT-1 is capable of utilizing both GABA and betaine as substrates. Betaine 
and GABA transport are both Na+- and Cl--dependent. A coupling ratio of Na+/Cl-
/organic substrate of 3:1:1 or 3:2:1 has been proposed (Matskevitch et al., 1999). 
Thus, BGT-1 can accumulate betaine inside the cell using the electrochemical 
gradient of sodium and chloride across the plasma membrane. Transport assay in 
oocytes expressing the canine BGT-1 reveals that the Km for betaine is 398 µM and 
for GABA is 93 µM, suggesting that BGT-1 has a higher affinity for GABA than 
betaine. However, in view of the fact that the concentrations of betaine in plasma (~ 
180 µM) far exceed those of GABA (< 1 µM), only betaine is accumulated to 
significant levels in the renal medulla (Yamauchi et al., 1992). It should be pointed 
out that BGT-1 is a weak transporter of GABA in comparison to other GABA 
transporters, given that the Km of GAT-1 for GABA is 7 µM and Km of GAT-3 for 
GABA is 0.8 µM (Guastella et al., 1990; Liu et al., 1993). 
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       Pharmacological investigations indicate that nipecotic acid and β-alanine are 
weak inhibitors for both betaine and GABA uptake by BGT-1 (IC50 value ≥ 2 mM), 
as examined in the expressed oocytes (Yamauchi et al., 1992). NNC 05-2090 
appears as a selective inhibitor of BGT-1 in inhibiting GABA uptake, showing at 
least 10 fold selectivity over GAT-1, GAT-2 and GAT-3 (Thomsen et al., 1997). 
      It is worth to note that Amino acid system transporter A might be able to 
transport betaine into cells when responding to hyperosmolarity (Petronini et al., 
1994). 
 
3.1.5. Transcriptional regulation of BGT-1 upon hyperosmolarity 
      Further investigations reveal that hyperosmolarity stimulates the transcription of 
BGT-1, leading to increased abundance of BGT-1 mRNA, increased transport 
activity of BGT-1 and subsequent accumulation of betaine in MDCK cells. When 
MDCK cells grown in isoosmotic medium are transferred to hyperosmotic culture 
medium, BGT-1 mRNA abundance has been shown to increase by both Northern 
Blot and ribonuclease protection assay (Yamauchi et al., 1992; Uchida et al., 1993). 
Transcription of the BGT-1 gene in response to hyperosmolarity, as examined by 
nuclear run-on assay, begins to rise within a few hours and reaches a peak at 
approximately 16 hours.  The time course and magnitude of BGT-1 mRNA level 
closely follow those of BGT-1 transcription and precede the changes in BGT-1 
transport activity by about 3-4 hours (Uchida et al., 1993). These results strongly 
indicate that the increase in transport activity of BGT-1 results from a 
 31
hyperosmolarity-induced increase in the transcription of BGT-1 gene and the 
resulting increase in BGT-1 synthesis.  
 
3.1.5.1. Tonicity-responsive enhancer (TonE) 
      Following the cloning of the entire BGT-1 gene from MDCK cells, a regulatory 
sequence element termed tonicity-responsive enhancer (TonE) has been identified in 
the promoter region of the BGT-1 gene. Detailed studies confirm that TonE 
mediates the transcriptional stimulation in response to hyperosmolarity. This is 
accomplished by transfection of luciferase reporter gene constructs containing 
various DNA fragments of the 5’- flanking region of the BGT-1 into MDCK cells, 
followed by luciferase assay under isoosmotic or hyperosmotic environment. Further 
studies by electrophoretic mobility shift assay (EMSA) expressing mutants of TonE 
reveal that TonE contains a sequence of TGGAAAAGTCCAG and spans between 
62 and 50 nucleotides upstream of the first exon of the BGT-1 gene. TonE acts in an 
orientation-independent manner and concatenation increases its function 
dramatically (Takenaka et al., 1994).  
       The function of TonE as an osmotic enhancer of transcription has also been 
demonstrated in vivo. Transgenic mice harboring 2.4 kb of the 5’-flanking region of 
the canine BGT-1 gene (including TonE) fused to the chloramphenicol 
acetyltransferase (CAT) reporter gene in their genome show increased expression of 
CAT in the renal medulla under systemic hyperosmotic conditions (Kaneko et al., 
1997). 
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3.1.5.2. Transcription factor TonEBP 
       Using yeast one-hybrid screening and affinity chromatography purification, the 
transcription factor TonEBP (TonE binding protein) has been identified (Miyakawa 
et al., 1999; Ko et al., 2000). The DNA binding domain of TonEBP shares a 45% 
identity with those of the NFAT family of transcription factors; TonEBP is thus also 
known as NFAT5 (Lopez-Rodriguez et al., 1999). The TonEBP sequence that is C-
terminal to the DNA binding domain contains many glutamine residues (18% of 
amino acids are glutamines). A truncated TonEBP without this glutamine-rich 
region acts as a dominant negative TonEBP, suggesting that this region mediates 
transcription activation (Miyakawa et al., 1999). TonBEP exists as a dimer, and 
dimerization is required for DNA binding and transcriptional activity (Lopez-
Rodriguez et al., 2001). The resolved crystal structure of TonEBP-DNA complex 
reveals that TonEBP binds to TonE target through base-specific contacts as well as 
DNA encirclement (Stroud et al., 2002). 
        In response to increased osmolarity, TonEBP undergoes different levels of 
regulation. Within 30 minutes of exposure to hyperosmolarity, TonEBP becomes 
phosphorylated and translocates into the nucleus (Miyakawa et al., 1999; Ko et al., 
2000; Dahl et al., 2001). Several hours later, the levels of TonEBP mRNA and 
protein as well as TonEBP activity, as measured by EMSA, increase significantly 
(Miyakawa et al., 1998; Miyakawa et al., 1999; Ko et al., 2000). In addition, it has 
been shown that hyperosmotic activation of TonEBP associates with 
phosphorylation of its transactivation domain (Ferraris et al., 2002b). 
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      TonEBP is widely expressed in human tissues, the highest levels being in the 
renal medulla, brain and heart (Handler and Kwon, 2001). Under isoosmotic 
conditions, TonEBP is roughly equally distributed between cytoplasm and nucleus 
in MDCK cells (Woo et al., 2000a; Woo et al., 2000b; Dahl et al., 2001). In contrast, 
TonEBP is located primarily within the nuclei of neurons and glials in normal 
isoosmotic rat. Following acute systemic hyperosmotic induction, rapid and strong 
overexpression of TonEBP in neuronal nuclei and slight overexpression of TonEBP 
in glia nuclei are observed in the brain (Loyher et al., 2004). 
 
3.1.5.3. Osmotic signaling pathway  
       The osmotic signaling pathway in yeast is well investigated. It includes both a 
two-component signal transducer and a Hog1 mitogen-activated protein kinase 
cascade. When yeast cells are exposed to hyperosmotic environment, the initial 
sensor Sln1p, a transmembrane protein containing cytoplasmic histidine kinase 
domain, initiates a multistep phosphorelay cascade that activates Hog1 kinase 
(Brewster et al., 1993; Han et al., 1994; Posas et al., 1996). Activated Hog1 directly 
participates in chromatin binding (Alepuz et al., 2001) and up-regulates the 
expression of a number of genes, including glycerol-3-phosphate dehydrogenase and 
glycerol-3-phosphatase isoform 2 (Posas et al., 2000; Rep et al., 2000). These two 
enzymes are required for the biosynthesis of glycerol, a dominant compatible 
osmolyte in yeast (Ohmiya et al., 1995; Pahlman et al., 2001). 
       In contrast, the osmotic signaling pathway in animal cells remains to be 
elucidated, although some kinase pathways are involved in TonEBP activation. To 
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date, the osmotic sensors have not been identified in mammalian cells. Studies have 
revealed that protein kinase A (PKA) activity is necessary for TonEBP-mediated 
osmotic response (Ferraris et al., 2002a). In addition to PKA, two other kinases, p38 
and Fyn, both contribute to activation of TonEBP (Ko et al., 2002). 
 
3.2. Taurine transporter (TauT) 
       Taurine transporter (TauT) cDNA has been cloned from numerous resources in 
mammalian species, e.g., MDCK cells (Uchida et al., 1992), mouse brain (Liu et al., 
1992a), rat brain (Smith et al., 1992), human thyroid (Jhiang et al., 1993), human 
placenta (Ramamoorthy et al., 1994) and bovine endothelial cells (Qian et al., 2000). 
TauT consists of 590-655 amino acids, and has molecular weight of 65-74 KDa. 
Mammalian TauTs share more than 90% amino acid sequence identity; belong to the 
Na+- and Cl--dependent family. Hydropathy plots reveal that TauT has 12 
transmembrane domains with the N-terminal and C-terminal both facing to the 
cytosolic side (Tappaz, 2004; Lambert, 2004). 
       Kinetic analysis suggests that TauT requires two Na+ ions and one Cl- ion to 
transport one taurine molecule across the plasma membrane. Km of TauT for taurine 
is in the low µM range and uptake of taurine is inhibited by β-alanine and 
hypotaurine (Foos and Wu, 2002; Chen et al., 2004). 
       Exposure of cells to a hyperosmotic medium results in increased Vmax of TauT 
and/or increased abundance of TauT mRNA (Tappaz, 2004). This has been 
consistently shown in a wide variety of cells, including liver endothelial cells (Weik 
et al., 1998), intestinal Caco-2 cells (Satsu et al., 1999), MDCK cells (Uchida et al., 
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1991; Uchida et al., 1992; Jones et al., 1995), astrocytes in primary cultures (Beetsch 
and Olson, 1996; Bitoun and Tappaz, 2000b) and brain capillary endothelial cells 
(Kang et al., 2002). Following acute salt-loading, a significant increase in the level 
of TauT mRNA has been detected in rat brain (Bitoun and Tappaz, 2000a). 
       Although the promoter region in TauT gene has been cloned and characterized 
(Han et al., 2000), no tonicity-responsive element has yet been identified for TauT. 
It has been shown that both PKA and PKC pathways are involved in the regulation 
of TauT activity (Tappaz, 2004). 
 
3.3. Myo-inositol transporter 
         As BGT-1, myo-inositol transporter cDNA was originally cloned from MDCK 
cell. A single protein of 718 amino acids with 12 transmembrane domains is 
deduced from its cDNA. Myo-inositol transporter belongs to the Na+-dependent 
transporter family, and is termed SMIT (sodium myo-inositol transporter) (Kwon et 
al., 1992). Transport of myo-inositol by SMIT is pH-dependent and requires two 
Na+ ions for one myo-inositol molecule; phlorizin is a potent competitive inhibitor 
(Hager et al., 1995). Subsequently, human SMIT gene was cloned (Berry et al., 
1995), and is a complex multiexon transcriptional unit subject to alternate splicing 
(Porcellati et al., 1998). 
        SMIT is widely distributed in the brain and present in both neural and non-
neural cells (Inoue et al., 1996). Upregulation of SMIT in response to 
hyperosmolarity has been shown in numerous studies, including in vitro cell culture 
(Paredes et al., 1992; Yamauchi et al., 1993; Strange et al., 1994; Wiese et al., 1996; 
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Isaacks et al., 1997), and in vivo preparations (Ibsen and Strange, 1996; Bitoun and 
Tappaz, 2000a). 
       It has been shown that transcription of SMIT gene can be regulated by multiple 
tonicity-responsive enhancers scattered throughout the 5'-flanking region of the gene 
(Rim et al., 1998). Activation of PKC could lead to an inhibition of SMIT activity in 
human astrocytoma cells (Batty et al., 1993). 
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4.  The GABAergic system in the central nervous system 
4.1. Metabolism of GABA 
        GABA (γ-aminobutyric acid) was discovered in mammalian brain in 1950 by 
Awapara et al. (Awapara et al., 1950) and by Roberts and Frankel (Roberts and 
Frankel, 1950). In 1970’s, GABA was identified as an inhibitory neurotransmitter in 
the adult mammalian brain (Roberts, 1976). GABA is widely distributed as 
GABAergic neuron and released at nearly 40% of brain synapses (Fonnum F, 1987; 
Sivilotti and Nistri, 1991). Lately, diverse functional role of GABA has been 
revealed. It acts as a neurotrophic factor (Barbin et al., 1993; Lauder et al., 1998), 
induces neural migration (Behar et al., 1994; Behar et al., 1996), and facilitates 
neurite extension (Behar et al., 1994; Owens and Kriegstein, 2002). 
        The metabolism of GABA in the brain is tightly linked to tricarboxylic acid 
(TCA) cycle in the mitochondria (Tillakaratne et al., 1995). Three enzymes, namely, 
glutamic acid decarboxylase (GAD, E.C. 4.1.1.15), GABA transaminase (GABA-T, 
E.C. 2.6.1.19) and succinic semialdehyde dehydrogenase (SSADH, E.C. 1.2.1.24) 
are responsible for GABA metabolism. Among them, GAD is a specific marker of 
GABAergic neurons. Two isoforms of GAD encoded by two distinct genes, GAD65 
and GAD67, are identified in GABAergic neurons. GAD65 is preferentially present 
near neuronal synaptic vesicles, where GAD67 is a soluble cytoplasmic protein 
(Soghomonian and Martin, 1998). GAD67 is responsible for the synthesis of >90% 
of GABA in the brain (Watanabe et al., 2002). 
       In mature brain, GABA is primarily produced through the decarboxylation of 
glutamic acid catalyzed by GAD. GAD is the rate-limiting enzyme for GABA 
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synthesis and requires pyridoxal phosphate as a cofactor. This reaction from 
glutamic acid to GABA is essentially irreversible (Roberts and Kuriyama, 1968). 
Precursor glutamic acid is derived from α-ketoglutarate generated by the TCA cycle 
and from glutamine catalyzed by phosphate-activated glutaminase (PAG). GABA 
may also be synthesized by other alternative routes, involving deamination and 
decarboxylation reactions from putrescine, spermine, spermidine and ornithine, but 
these routes do not contribute significantly to the synthesis of GABA in the brain 
(Martin, 1993). 
        GABA catabolism is catalyzed by the mitochondrial enzyme GABA-T, which 
transfers the amino group from GABA to α-ketoglutarate, producing glutamate and 
succinic semialdehyde. The resulting succinic semialdehyde is rapidly converted by 
the mitochondria enzyme SSADH into succinate, which enters the TCA cycle. 
During this procedure, GABA-T serves as both a synthetic (production of glutamate) 
and degradative (degradation of GABA) enzyme. This particular dual role allows the 
conservation of the transmitter pool of GABA. The metabolism of GABA is often 
called the “GABA shunt”, because it bypasses the TCA cycle (Tillakaratne et al., 
1995).    
        GABA is synthesized exclusively by GABAergic neurons in the brain. In 
contrast, GABA-T and SSADH, the two enzymes required for GABA catabolism, 
are also present in non-GABAergic neurons, e.g., astrocytes. Glial cells are 
responsible for the degradation of GABA that is not recaptured by the GABAergic 
terminal (Martin, 1993). In glial cells, the glutamate formed from the GABA 
degradation is converted into glutamine, which is catalyzed by the cytosolic enzyme 
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glutamine synthetase (GS). The resulting glutamine is exported to neurons and 
converted to glutamate by the mitochondrial enzyme PAG. Therefore, glial 
glutamine is an important precursor for both neuronal glutamate and GABA (Farrant, 
2002). For a summary of GABA metabolism in the context of a GABAergic synapse, 
refer to Figure 2. 
 
4.2. Function of released GABA 
       Once released from GABAergic axon terminal, GABA molecules act on GABA 
receptors. To date, three types of GABA receptors have been identified: GABAA, 
GABAB and GABAC. The GABAA and GABAC receptors belong to the ligand-gated 
Cl- channel superfamily and mediate the fast inhibitory action of GABA. GABAA 
receptor is widely distributed in the brain and located at postsynaptic membrane. In 
contrast, GABAC receptor is expressed predominantly in the retina. Structurally, 
GABAA and GABAC receptors are both pentameric heterooligomer. Drugs such as 
benzodiazepines and barbiturates enhance GABAA receptor-mediated inhibition, and 
they are clinically important anticonvulsant (Chebib and Johnston, 2000; Watanabe 
et al., 2002; Farrant, 2002). 
         GABAB receptor is a GTP-binding protein-coupled receptor, and thus differs 
from the GABAA and GABAC receptor pharmacologically as well as 
electrophysiologically. Two main GABAB receptor subunits encoded by distinct 
genes have been identified, named GABABR1 and GABABR2 (Isomoto et al., 1998; 
Kaupmann et al., 1998). The native structure of GABAB receptor may be a 
heterodimer of GABABR1 and GABABR2 through an interaction between the coiled 
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regions of their intracellular C-termini (Kuner et al., 1999; Marshall et al., 1999). 
GABAB receptor is present at postsynaptic membrane of inhibitory synapse, as well 
as both excitatory and inhibitory axon terminals. Activation of postsynaptic GABAB 
receptors results in the activation of K+ channels and subsequent hyperpolarization 
of the postsynaptic membrane. On the other hand, activation of presynaptic GABAB 
receptors leads to the inhibition of neurotransmitter release from presynaptic 
terminals. This inhibition attributes to the blocking of presynaptic voltage-gated 
Ca2+ channels (Bowery and Enna, 2000; Watanabe et al., 2002). 
       GABAB receptor plays an important role in modulation of neurotransmitter 
release. Baclofen, a selective agonist of GABAB receptor, decreases 
neurotransmitter release in the brain (Bowery et al., 1980). Baclofen has been shown 
to suppress epileptiform electrical activity in the hippocampus (Swartzwelder et al., 
1986). Presynaptically, GABAB autoreceptor controls the release of GABA, while 
GABAB heteroreceptor regulates the release of glutamate, dopamine, noradrenalin, 
5-hydroxytryptamine and somatostain (Watanabe et al., 2002). 
       In addition to acting on GABA receptors, GABA released from the presynaptic 
axon terminals, is largely removed by uptake into both glial cells and GABAergic 
neurons through high-affinity GABA transporters. Once recovered into glial cells or 
GABAergic neurons, GABA undergoes catabolism as described above. Vigabatrin, 
an irreversible inhibitor of GABA-T, can increase the levels of brain GABA and has 




4.3. Plasma membrane GABA transporters 
        In the 1960s, studies have revealed the existence of specific plasma membrane 
transport proteins for GABA in the mammalian brain (Varon et al., 1964; Iversen 
and Neal, 1968; Iversen and Neal, 1969). In the year 1990, cloning and expression 
of the first GABA transporter (GAT-1) from rat brain is the starting point for the 
characterization of related plasma membrane GABA transporters (Guastella et al., 
1990). To date, four plasma membrane GABA transporters, termed GAT-1, GAT-2, 
GAT-3, and BGT-1 have been cloned and identified according to their differential 
amino acid sequences and pharmacological properties. They show approximately 
50% amino acid sequence similarity, and belong to the family of Na+- and Cl--
dependent neurotransmitter transporters with 12 putative transmembrane spanning 
domains. Both fairly large N- and C-terminal domains containing potential 
phosphorylation sites are situated at the cytoplasmic side (Masson et al., 1999; 
Soudijn and Van Wijngaarden, 2000).  
        The plasma membrane GABA transporters mediate high-affinity GABA uptake 
into presynaptic axon terminals and glial processes, thereby regulating the 
magnitude and duration of GABA synaptic action (Isaacson et al., 1993; Mager et al., 
1993). Additional function of GABA transporters is that by removing GABA, they 
allow it to be reused, either directly or indirectly (Borden, 1996).  The plasma 
membrane GABA transporters may also release GABA into the extracellular space 
in a Ca2+-independent, non-vesicular manner (Pin and Bockaert, 1989; Attwell et al., 
1993). This can occur in ischemia or seizures, due to the changes in the 
transmembrane sodium or voltage gradient. The reversal functioning of GABA 
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transporters could exert a protective effect during seizures, by reducing electrical 
excitability (Phillis et al., 1994; Borden, 1996). 
        It is worth to note that there exist specific vesicular membrane GABA 
transports, which carry GABA molecules into synaptic vesicles. Two vesicular 
membrane GABA transporters have been identified in the brain, named VGAT and 
VIAAT (McIntire et al., 1997; Sagne et al., 1997). 
       The followings give a detailed characterization of plasma membrane GABA 
transporters, GAT-1, GAT-2 and GAT-3. For BGT-1, refer to the above descriptions. 
 
4.3.1. GAT-1   
       The pioneering work of cloning and identification of the first neurotransmitter 
transporter, GAT-1, was accomplished by Kanner and colleagues through an 
international collaboration. A GABA transporter from rat brain was first purified to 
homogeneity and microsequenced. Oligonucleotide probes designed according to the 
corresponding amino acid sequence were then used for screening a rat brain cDNA 
library. The isolated rat GAT-1 cDNA was subsequently expressed in Xenopus 
oocytes to examine its functional properties. The rat GAT-1 cDNA predicts a protein 
of 599 amino acids with a molecular weight of 67 kDa. Hydropathy analysis reveals 
that GAT-1 is a single protein of 12 transmembrane domains, with three potential 
glycosylation sites on the putative extracellular loop between transmembrane 
domain 3 and 4. Pharmacological studies indicate that uptake of GABA by GAT-1 is 
more sensitive to ACHC and L-DABA than to β-alanine, a feature traditionally 
known as the neuronal GABA transporter (Radian et al., 1986; Guastella et al., 
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1990). GAT-1 has also been cloned from human (Nelson et al., 1990) and mouse 
brains (Liu et al., 1992b), exhibiting 97% and 99% sequence identity with rat GAT-
1 respectively. Electrophysiological studies on GAT-1 in diverse expression systems, 
including synaptosomes, Xenopus oocytes and mammalian cells, show the 
cotransport of one GABA molecule with two Na+ and one Cl- (Keynan et al., 1992; 
Mager et al., 1993; Mager et al., 1996; Risso et al., 1996). 
       In contrast to BGT-1, GAT-1 is expressed exclusively in the central nervous 
system (Gadea and Lopez-Colome, 2001). Use of radiolabelled oligonucleotide 
probes and in situ hybridization histochemistry reveals that GAT-1 mRNA is widely 
spread in the brain, including retina, olfactory bulb, neocortex, ventral pallidum, 
hippocampus and cerebellum. Overall, the distribution of GAT-1 mRNA in the brain 
matches closely with that of GABAergic neurons, as examined by the localization of 
GABA or GAD. However, in cerebellum, GABAergic Purkinje cells do not express 
GAT-1 mRNA, whilst Bergmann glia cells express high levels of GAT-1 mRNA 
(Rattray and Priestley, 1993; Durkin et al., 1995; Borden, 1996). 
Immunohistochemical studies using antibodies to GAT-1 have consistently shown 
that GAT-1 is present in axon terminals of GABAergic neurons and also in 
astrocytic processes in rat brain (Radian et al., 1990; Minelli et al., 1995; Johnson et 
al., 1996; Ribak et al., 1996a; Ribak et al., 1996b). GAT-1 has been localized to 
non-pyramidal neurons in human and monkey cerebral cortex (Conti et al., 1998; 
Ong et al., 1998), but is also found in astrocytic processes in human and monkey 
cerebral cortex (Conti et al., 1998).  
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     Various studies have demonstrated the alterations of GAT-1 expression in 
epilepsy. An increase in GAT-1 mRNA was detected bilaterally in the rat 
hippocampal CA subfields and dentate gyrus at 4 hour earlier after amygdala-
kindled seizures (Hirao et al., 1998). The expression of GAT-1 protein increases 
bilaterally in the rat hippocampus at 5 to 15 days, and returns to normal levels by 30 
days in focal epilepsy induced by amygdaloid ferric iron injection (Ueda and 
Willmore, 2000). In contrast, reductions in GAT-1 mRNA in various brain regions 
have been shown in genetically epileptic-prone rats following audiogenic stimulus 
(Akbar et al., 1998). A decreased GAT-1 expression is also found in the CA3 region 
of epilepsy patients with mesial temporal sclerosis (Mathern et al., 1999). During et 
al. have demonstrated the impaired function of GABA transporters in the human 
epileptic hippocampus (During et al., 1995).  
       GABA analogues, e.g., nipecotic acid and guvacine, have been studied as 
inhibitors for GAT-1. However, due to their poor penetration through the BBB, 
these inhibitors are of experimental interest only. Recently, a variety of potent and 
selective inhibitors of GAT-1 have been synthesized, with nipecotic acid or 
guvacine coupled to a lipophilic moiety, e.g., NNC-711, Tiagabine, SK&F 89976-A 
and Cl-966. These lipophilic inhibitors display anticonvulsant activity in vivo, 
probably due to the prolonged action of synaptically released GABA. Of these, 
Tiagabine has proved clinically useful in the treatment of epilepsy (Borden, 1996; 





      GAT-2 cDNA has been first isolated from a rat brain cDNA library by 
homologous screening. It has a predicted open reading frame of 1806 nucleotides 
encoding a protein of 602 amino acids. GAT-2 is also present in liver and kidney as 
examined by Northern blot and RT-PCR (Borden et al., 1992). Mouse GAT-2 
(originally termed mouse GAT-3) has also been cloned, and it shares a 51% amino 
acid identity with mouse GAT-1. Mouse GAT-2 has a much lower affinity for 
GABA than mouse GAT-1 (Liu et al., 1993). 
        GAT-2 is present primarily in the leptomeninges, choroid plexus and ependyma 
of the rat brain (Ikegaki et al., 1994; Durkin et al., 1995; Conti et al., 1999). Within 
the rat retina, GAT-2 is localized to the retinal pigment epithelium layer, nerve fiber 
layer and ciliary body epithelium (Honda et al., 1995; Johnson et al., 1996). 
       A role for GAT-2 in regulating GABA levels in the cerebrospinal fluid has been 
proposed (Conti et al., 1999). Since mRNA levels of GAT-2 are more abundant in 
neonatal than in adult mouse brain, GAT-2 might play a role in mouse development 
(Liu et al., 1993; Gadea and Lopez-Colome, 2001). 
 
4.3.3. GAT-3 
       GAT-3 is initially cloned from the rat brain using cDNA library homologous 
screening technology. Its cDNA has an open reading frame of 1881 nucleotides 
encoding a protein of 627 amino acids. GAT-3 predicts a single protein of 12 
transmembrane domains with multiple putative glycosylation sites on the 
extracellular loop between transmembrane domain 3 and 4. GAT-3 displays a 52% 
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amino acid identity with GAT-1. Northern blot and RT-PCR analysis reveal that 
GAT-3 mRNA is restricted to the brain. Uptake of GABA by GAT-3 is more 
sensitive to β-alanine than to ACHC, guvacine and nipecotic acid, a property 
traditionally known as the glial GABA transporter (Borden et al., 1992). 
Subsequently, GAT-3 is cloned from human and mouse brain (originally termed 
mouse GAT-4) (Liu et al., 1993; Borden et al., 1994). Interestingly, GAT-3 
possesses the highest affinity for GABA among the four plasma membrane GABA 
transporters isolated from mouse brain (Liu et al., 1993).  A lipophilic inhibitor with 
selectivity for GAT-3, (S)-SNAP-5114 has been developed. Due to its ability to 
effectively cross the BBB, it may serve as an important tool for evaluating the 
functional role of GAT-3 in the brain (Borden et al., 1994). 
        GAT-3 mRNA is widely expressed in the brain, as examined by radiolabelled 
oligonucleotide probes and in situ hybridization histochemistry (Durkin et al., 1995). 
Immunocytochemical studies reveal that GAT-3 is localized to astrocytic processes 
in the monkey and rat brain (Minelli et al., 1996; Ribak et al., 1996b; Ng et al., 
2000). It is also found in a population of oligodendrocyte-like cells in the rat spinal 
trigeminal nucleus (Ng and Ong, 2001). 
       Changes in GAT-3 expression in epilepsy have been shown. GAT-3 mRNA 
increases bilaterally in the amygdalar nuclei and in the contralateral pyriform cortex 
and cerebral cortex at 1 hour earlier after amygdala-kindled seizures in the rat (Hirao 
et al., 1998). The protein levels of GAT-3 in the rat hippocampus undergo 
upregulation following focal epilepsy induced by amygdaloid ferric iron injection 
(Ueda and Willmore, 2000). An increase in GAT-3 protein expression has been 
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demonstrated in the hilus and Ammon’s horn in patients with temporal lobe epilepsy 
(Mathern et al., 1999).  
 
5. Excitotoxic brain injury  
5.1. Experimental models of excitotoxcity - Kainate injections 
         Kainic acid (KA) [2-carboxy-4(1-methyl-ethenyl)-3-pirrolidinacetic acid] is a 
structural analog of the excitatory amino acid, glutamate that binds to and activates 
ionotropic, non-NMDA glutamate receptors (Honore et al., 1987; Kaczmarek et al., 
1997).  It is 30- to 100-fold more potent than glutamate as a neuronal excitant. 
Systemic and intracerebral administrations of KA into adult rats induce persistent 
seizures and seizure-mediated brain damage syndrome (Nadler et al., 1978; Coyle, 
1983; Sperk, 1994). Within 1 hour after KA injection into the rats, the neuronal 
circuitry of the hippocampus are activated, and later the animals develop symptoms 
of robust and recurrent seizures, such as vibrissa tremor, distended eye, upper body 
tremor, rigidity of the limbs and foaming at the mouth. Pyramidal neurons in the 
CA1 and CA3 fields of the hippocampus begin to degenerate at 3-4 days post KA 
injection (Nadler et al., 1986; Ben Ari and Cossart, 2000). KA treated rats have been 
widely used as a model for studying human temporal lobe epilepsy (Nadler, 1981; 
Ben Ari, 1985; Sutula, 1990; Sloviter, 1996). 
         After intraventricular or intracerebral administration, KA produces selective 
degenerations of neurons, especially in striatal and hippocampal areas of the brain. 
Axons and nerve terminals are more resistant to the destructive effects of KA than 
the cell soma (Coyle, 1983; Lerma, 1997). Intraventricular KA injections cause 
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neuronal death of the affected CA subfields in the hippocampus (Nadler et al., 1978; 
Malhotra et al., 1990; Ong et al., 1996). In this case, the CA3 subfield ipsilateral to 
the injection suffers the greatest cellular damage, whilst the neurons in CA1 subfield 
often survive the KA insult (Nadler et al., 1978; Nadler et al., 1980; Schwob et al., 
1980). Also, injections of KA into amygdaloid complex of rats result in pronounced 
cell death in CA3 subfield (Ben Ari et al., 1980; Pollard et al., 1994a; Pollard et al., 
1994b). Aside from neurodegeneration, one of the prominent findings in 
intraventricular KA injection is the glia reaction in the lesioned area. It is 
characterized by proliferation and hypertrophy of glial cells in the glial scar 
(Malhotra et al., 1990; Jorgensen et al., 1993; Ong et al., 1996). 
          In addition, administration of KA into the ventral globus pallidus (basal 
forebrain region) of rats produces neurodegeneration of cholinergic neurons, a 
pattern similar to nerve cells loss in Alzheimer’s disease (Johnston et al., 1979). The 
neuronal excitation caused by KA results in the upregulation of a variety of genes in 
the hippocampus. These include immediate-early genes, cytokines and membrane 
transporters (Minami et al., 1991; Simantov et al., 1999; Zagulska-Szymczak et al., 
2001). 
 
5.2. Osmotic stress in excitotoxcity 
         Following KA injections, macroscopic inspection reveals the volume change in 
the affected brain region. Brains obtained from rats sacrificed shortly after KA 
systemic administration show an increase in the volume of hemisphere. The 
temporal lobe shows incisures and appears to be swollen (Sperk, 1994). In rats that 
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received intraventricular KA injection, the hippocampus, especially ipsilateral to the 
injection, suffers pronounced shrinkage at late stage. Histopathological findings 
during the early stage after KA administration include shrinkage and pycnosis of 
neuronal perikarya and swelling of dendrites and astrocytes (Olney et al., 1979; 
Schwob et al., 1980; Murabe et al., 1982; Sperk et al., 1983). 
       Osmotic stress occurs in KA-induced neuronal injury. KA has been shown to 
produce focal swelling on the dendrites of hippocampal interneuron and primary 
cortical cultures (Hasbani et al., 1998; Al Noori and Swann, 2000). Upon neuronal 
excitation, massive influx of ions, particularly Na+, Cl- and Ca2+, leads water to flow 
into neurons and glial cells, and thus cause cellular swelling (Rothman, 1985; Olney 
et al., 1986; Choi, 1987; Meyer, 1989). A large number of voltage/ligand- gated ion 
channels, pumps (e.g. Na+, K+-ATPase), exchanges (e.g. H-Na exchange) and 
transporters (e.g. Na, K, 2Cl transporter) are involved in ion movement into or out of 
cells (Schwartzkroin et al., 1998). In the case of KA induced neuronal injury, the 
degenerated neurons also release its content into the extracellular space. As a result, 
dynamic changes in intracellular/extracellular osmolarity in neurons and glial cells 
occur during neurodegeneration. In fact, changes in osmolarity affect neuronal 
excitability (Andrew, 1991; Roper et al., 1992; Saly and Andrew, 1993; Huang et al., 
1997). 
        The involvement of osmolyte transporter in KA induced neuronal injury has 
been reported. Use of Northern Blot and in situ hybridization detects the 
upregulation in the mRNA level of Na+ / myo-inositol cotransporter in amygdala, 
hippocampus and neocortex after KA systemic injection (Nonaka et al., 1999). It is 
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worth to note that osmolytes including betaine, taurine and myo-inositol have been 
demonstrated to attenuate seizure activity in the rats (Freed, 1985; Ghoz and Freed, 
1985; Williams and Jope, 1995; Patishi et al., 1996; El Idrissi et al., 2003). 
6. Aims of experimental studies 
       Osmoregulation in the brain is critical for maintaining a constant milieu in the 
brain, since the skull is a rigid, non-expandable container, and changes in ion 
composition would affect excitability (Strange, 1992; Gullans and Verbalis, 1993; 
Law, 1994a; Lang et al., 1998). The osmolyte transporters might play a key role in 
osmoregulation in the brain. The expression of taurine transporter (TauT), myo-
inositol transporter (SMIT), and betaine / GABA transporter (BGT-1) mRNA levels, 
for instance, were increased in the brain following acute salt loading (Bitoun and 
Tappaz, 2000a). Of the three transporters, SMIT and BGT-1 mRNA were increased 
in all brain regions studied, i.e. the cerebral cortex, striatum and habenula (Bitoun 
and Tappaz, 2000a). 
         BGT-1 was first cloned from Madin-Darby canine kidney (MDCK) cells, and 
shown to transport both betaine and GABA (Yamauchi et al., 1992). Subsequently, 
it is cloned from the mouse brain (originally named mouse GAT-2) (Lopez-Corcuera 
et al., 1992), human kidney (Rasola et al., 1995), human brain (Borden et al., 1995b), 
rat liver (Burnham et al., 1996)  and  rabbit renal papilla cells (Ferraris et al., 1996). 
BGT-1 shares sequence similarity with the plasma membrane GABA transporters: 
GAT-1, GAT-2, GAT-3, and belongs to the family of Na+- and Cl--dependent 
neurotransmitter transporters with 12 putative transmembrane spanning domains 
(Borden, 1996; Masson et al., 1999; Soudijn and van, I, 2000). 
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         The plasma membrane GABA transporters terminate the synaptic action of 
GABA. The expressions of GAT-1, GAT-2 and GAT-3 in the brain have been 
studied by immunocytochemistry. GAT-1 is present in axon terminals of 
GABAergic neurons and also in astrocytic processes in rat brain (Radian et al., 1990; 
Minelli et al., 1995; Johnson et al., 1996; Ribak et al., 1996a; Ribak et al., 1996b). 
GAT-1 is also found in non-pyramidal neurons in human and monkey cerebral 
cortex (Conti et al., 1998; Ong et al., 1998), and in astrocytic processes in human 
and monkey cerebral cortex (Conti et al., 1998). GAT-2 is present primarily in the 
leptomeninges, choroid plexus and ependyma in rat brain (Ikegaki et al., 1994; 
Durkin et al., 1995; Conti et al., 1999). GAT-3 is only found in glial cells, including 
astrocytes and a population of oligodendrocyte-like cells in the monkey and rat 
brains (Minelli et al., 1996; Ribak et al., 1996b; Ng et al., 2000; Ng and Ong, 2001).  
        In contrast, the distribution and function of BGT-1 in the brain have not been 
fully elucidated. An examination on the distribution of BGT-1 mRNA in human 
brain suggests that BGT-1 might not contribute to the removal of the synaptic 
GABA (Borden et al., 1995b). However, BGT-1 might contribute to osmoregulatory 
function in the brain, since betaine, which has been widely used as a non-perturbing 
osmolyte to compensate for hyperosmotic stress (Yancey et al., 1982; Burg, 1995), 
is a substrate for BGT-1. 
 The followings are the main aims of this present study. 
 
6.1. Study of distribution and subcellular localization of betaine/GABA 
transporter BGT-1 in the monkey cerebral neocortex and hippocampus 
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      BGT-1 mRNA has been detected by Northern blot and in situ hybridization in 
mouse, rat and human brain (Lopez-Corcuera et al., 1992; Borden et al., 1995b; 
Burnham et al., 1996). However, little is known about the distribution of BGT-1 in 
the brain, especially in primates, and at the ultrastructural level. This portion of the 
study was carried out, using immunocytochemistry and electron microscopy, to 
elucidate the distribution of BGT-1 in the monkey cerebral neocortex and 
hippocampus. 
 
6.2. Study of changes in the expression of GABA transporters in the rat 
hippocampus after kainate induced neuronal injury  
      Intraventricular KA injections, a model of temporal lobe epilepsy, causes 
neuronal death of the affected CA subfields in the hippocampus, and proliferation 
and hypertrophy of glial cells in the glial scar (Nadler et al., 1978; Malhotra et al., 
1990; Ong et al., 1996). To date, little is known about the effects on the expression 
of GABA transporters after this form of neuronal injury. Since changes in 
expression of GABA transporters / BGT-1 might result in alterations in levels of 
GABA / betaine in the extracellular space, with consequent effects on neuronal 
excitability or osmolarity, this portion of the study was carried out to explore the 
expression of GABA transporters including BGT-1 in the rat hippocampus, 
following KA-induced neuronal injury. 
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6.3. Study of differential effects of betaine and sucrose on BGT-1 expression 
and betaine transport in human U373MG astrocytoma cells and rat 
hippocampal astrocytes 
       In the above studies, BGT-1 immunoreactivity was observed in pyramidal 
neurons in the monkey and rat cerebral neocortex and the CA fields of hippocampus. 
BGT-1 expression decreased in neurons but increased in astrocytes after neuronal 
injury induced by KA. Numerous studies have revealed that osmotic overloading 
occurs following KA-induced neuronal injury (Rothman, 1985; Olney et al., 1986; 
Hasbani et al., 1998; Al Noori and Swann, 2000).  High levels of betaine (100-300 
mM) have been detected in single neurons isolated from the abdominal ganglion 
from Aplysia californica using the technique of NMR spectroscopy (Grant et al., 
2000).  In view of the known function of betaine as an osmolyte, one possible 
function of the upregulated BGT-1 might be to protect the astrocytes against 
increased osmotic stress. On the other hand, it might also be possible that excessive 
or prolonged BGT-1 expression might be a factor contributing to astrocytic swelling 
after brain injury. Till date, BGT-1 expression has been studied in astrocytes at the 
mRNA level (Bitoun and Tappaz, 2000b), but little is known about BGT-1 
expression at the protein level, or whether increased BGT-1 is associated with 
increased betaine transport. It is also not known whether betaine could induce the 
expression of BGT-1. This portion of the study was therefore carried out, to 
elucidate the changes in BGT-1 expression at protein level and the accompanied 
betaine uptake activity in vitro, as well as the changes in BGT-1 expression at 
















1. Animals   
        Six adult male or female monkeys (Macaca fascicularis) weighing 1.5-3.5 kg 
were used in this study, of which, two were used for Western Blot analysis and four 
were used for immunohistochemical analysis. A total of fifty-two adult male Wistar 
rats each weighing approximately 200-250 g was used in this study. Monkeys and 
rats are from Department of Anatomy of NUS, Laboratory Animals Center of NUS, 
respectively. All the rats received intracerebroventricular drug injection, among 
which, forty-eight rats were used for immunohistochemistry and the remaining four 
were used for Western blot analysis.  
        Prior to surgery or perfusion, all monkeys were deeply anaesthetized with an 
intraperitoneal injection of Nembutal (30 mg/kg), and all rats were deeply 
anaesthetized by an intraperitoneal injection of 1.2 ml of 7% chloral hydrate 
administered in the lower abdomen. Animals were required and cared for in 
accordance with guidelines published in the NIH Guide for the Care and Use of 
Laboratory Animals. All procedures involving animals were approved by the 
Medical Faculty Ethics Committee, National University of Singapore. 
 
2. Drug intracerebroventricular injection 
2.1. Kainate injection 
        Adult male Wistar rats were injected with kainate (Tocris, Bristol, UK). They 
were anaesthetized with an intraperitoneal injection of 1.2 ml 7% chloral hydrate, 
and the cranial vault exposed. KA (1 µl of a 1 mg/ml solution in saline) was injected 
into the right lateral ventricle (coordinates: 1.0 mm caudal to bregma, 1.5 mm lateral 
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to the mid-line, 4.5 mm from the surface of the cortex) using a Hamilton syringe 
(Hamilton, Reno, USA). The needle was withdrawn 10 min later, and the scalp 
sutured. This resulted in seizures after the rats had recovered from the anaesthesia. 
The experimental controls received an intracerebroventricular injection of 1 µl of 
normal saline. These rats were sacrificed at 3 days, 1 week, and 3 weeks after 
injection (four kainate injected and four saline injected rats at each time point) for 
perfusion. 
  
2.2. Kainate and betaine injection 
       Rats firstly received kainate injection via right lateral cerebral ventricle, as 
descried above. At 1 day postinjection, experimental rats were injected 
intracerebroventricularly in the right ventricle with a solution of 10 µl of 100 mM 
betaine (Sigma-Aldrich, St Louis, USA, dissolved in normal saline) and control rats 
were injected intracerebroventricularly with saline. These rats were sacrificed on the 




3. Western immunoblot analysis 
3.1. Solutions 
Homogenization buffer: 0.32 M sucrose, 4 mM Tris-Cl, pH 7.4, 1 mM EDTA and 
0.25 mM DTT 
      
Ringer’s solution:  
                               NaCl: 85g 
                               KCl: 2.5g 
                               CaCl2: 3g 
                               NaHCO3: 2g   
                              Topped up with distilled water to 10 liters, without pH adjustment 
 
 
Reagents and solutions for acrylamide gel 
Solutions for preparing 10% separating gel for Tris-glycine SDS-Polyacrylamide 
Gel Electrophoresis (10 ml) 
30% acrylamide mix 2.5 ml 
1.5 M Tris-HCl  (pH 8.8) 2.5 ml 
H2O 4.8 ml 
10% SDS 0.2 ml 
10% ammonium persulfate 35 µl 
TEMED 7.5 µl 
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 Solutions for preparing 5% stacking gel for Tris-glycine SDS-Polyacrylamide Gel 
Electrophoresis (5ml) 
30% acrylamide mix 0.85 ml 
1.0 M Tris-HCl  (pH 6.8) 1.28 ml 
H2O 2.78 ml 
10% SDS 51.23 µl 
10% ammonium persulfate 25 µl 
TEMED 5 µl 
 
Running buffer: SDS/Glycine electrophoresis buffer 
                         Tris base                            3.02 g/L 
                         Glycine                              14.4 g/L 
                         SDS                                    1 g/L 
     
Transfer buffer: 
                         (25 mM) Tris                       3.03 g 
                        (192 mM) Glycine                  14.4 g 
                         20% Methanol                       200 ml 




TBS solution (pH 7.6) 
                         Tris                                        2.42 g/L 
                         NaCl                                      8 g/L 
 
Washing buffer: 0.01% TTBS 
                         TBS                                        1 L 
                         Tween 20                                0.1 ml 
 
Blocking buffer: 5% BSA in washing buffer 
                         BSA                                         5 g 
                         Washing buffer                        100 ml 
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3.2. Protein extraction 
      Animals were first deeply anaesthetized and the brains removed. Blocks 
consisting of the liver and hippocampus were removed and homogenized in 10 
volumes of ice-cold homogenization buffer. After centrifugation at 1000g for 15 min, 
the supernatant was collected. Protein concentrations in the preparation were 
measured by the Bio-Rad protein assay kit using a spectrophotometer, as described 
below.  
 
3.3. Measurement of protein concentration 
Procedures: 
(1) The dye reagent was prepared by diluting 1 part Dye Reagent Concentrate with 4 
parts deionized water. 
(2) Five dilutions of the BSA standard were prepared. 
(3) 200 µl of diluted dye reagent was added to separate microtiter plate wells. 
(4) 10 µl of each BSA standard, deionized water and sample solutions were pipetted 
into each well. Mix the sample and reagent thoroughly. 
(5) Incubated at room temperature for 10 minutes, and measured absorbance at 595 
nm using a microplate reader. 




3.4. Separation of proteins by running SDS-PAGE gel 
Procedures: 
(1) The protein concentration in each sample was measured and 2 parts of Laminal 
buffer (Bio-Rad, Hercules, USA) were added. Samples were heated at 95 °C in 
water bath for 4 minutes and cooled down to room temperature. 
 (2) Gel solution was poured into a gel sandwich using a Bio-Rad Minigel apparatus. 
Deionized water was added on the top of the gel to keep the gel surface flat. The gel 
was allowed to polymerize for 40 minutes. Subsequently, the stacking gel was 
poured into the gel sandwich. A comb was carefully inserted into the stacking gel 
and allowed to polymerize for 20 minutes. 
 (3) The gel sandwich was put into a Mini-protean electrophoresis chamber (Bio-
Rad). A 300 ml of running buffer was added to cover the gel. Sample containing 70 
µg protein and protein marker were loaded carefully into each well. The electrode 
plugs were attached to proper electrodes. Constant voltage was set at 140 V and the 
gel was run for 75 minutes. 
 
3.5. Transferring protein from SDS-PAGE gel to polyvinylidine difluoride 
(PVDF) membrane 
        When the dye front migrated to 1 cm proximal to the bottom of gel, the power 
was turned off. The gel and two sheets of filter paper, which were of similar size to 
the gel, were immersed into the transfer buffer for 15-30 minutes. PVDF membrane 
was pre-wetted in methanol, followed by equilibrating in transfer buffer for at least 
10 minutes. The blotting sandwich was assembled according to the instruction of 
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wet transfer method (Mini TransBlot, Bio-Rad). The proteins were transferred from 
gel to PVDF membrane at 200 mA constant current for 90 minutes. 
 
3.6. Detection of protein using antibody 
       After transferring, the membrane was washed with distilled water and then 
soaked in blocking buffer on a rocking platform for 1 hour. The PVDF membrane 
was then incubated overnight in an affinity-purified rabbit polyclonal antibody to 
BGT-1 (Chemicon, Temecula, USA, diluted 4 µg/ml). After washing in washing 
buffer three times at 10 minutes each, the membrane was incubated with horseradish 
peroxidase conjugated goat anti-rabbit IgG (Amersham, Little Chalfont, UK) for 1 
hour at room temperature. Following three washes at 10 minutes each, the reaction 
was developed with the supersignal west pico chemiluminescent substrate (Pierce, 
Rockford, USA). The membrane was incubated for 5 minutes at room temperature 
without agitation and put into a plastic wrap. In the dark room, a Hyperfilm 
(Amersham) was placed on top of the membrane and exposed for 30 sec to 1 minute. 









                                    4% paraformaldehyde (PF) 
                                                        PF 40 g 
                                                         0.1 M phosphate buffer (pH 7.4) 1000 ml 
                                                         The pH was adjusted to 7.4 by adding 1N HCl 
solution. 
      The PF solution was prepared by heating paraformaldehyde powder in 0.1 M 
phosphate buffer (pH 7.4). It was subsequently cooled to the room temperature. For 
immunoperoxidase staining, glutaraldehyde (0.1%) was added into the PF solution 
before perfusion. However, the glutaraldehyde was omitted for tissues intended for 
double immunofluorescence staining.  
 
 Procedures: 
          A fully exposed heart was first made by the surgical removal of sternum and 
ribs. Perfusion was performed under gravity with the reservoirs containing the 
fixative and Ringer’s solution fixed at a height of about 100 cm above the animal. 
Perfusion was carried out by an insertion of a cannula into the left ventricle, 
followed by slitting a portion of the right atrium. A Ringer’s solution was used to 
flush the vascular system until the lungs and liver were cleared of blood. The 
fixative was then administered for at least 1 hour.   
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4.2. Tissue preparations  
Preparation of gelatinized slides: 
                         1.5% gelatin solution: 
                                               Gelatin: 1.5 g 
                                                Distilled water: 100 ml 
                                                Heat until dissolved. Cool and then add: 
                                                Chrome alum: 0.15 g 
 
Procedures: 
       Slides were first dipped in the acid solution (400 ml of 98% sulfuric acid mixed 
with 1 tea spoon of potassium dichromate) for 2min, and then washed by running 
tap water for 10min. The slides were rinsed with distilled water and then baked in an 
oven at 80 °C overnight for drying. The following day, dried slides were dipped in 
the gelatin solution and then hung to dry with clips. Gelatinized slides were kept in 
an oven at 37 °C for mounting tissue sections for use in histological or 
immunohistochemical studies.  
 
Preparation of vibratome sections: 
      The brains were bisected, and blocks including the left and right temporal cortex 
and hippocampus were removed and post-fixed in the same fixative overnight. 
Blocks containing the hippocampus were sectioned coronally at 100 µm thickness 




Preparation of frozen sections: 
       The brains were bisected, and blocks including the left and right temporal cortex 
and hippocampus were removed and post-fixed in the same fixative for additional 2 
hours. The tissues were subsequently transferred to a 0.1 M phosphate buffer (pH7.4) 
containing 15% sucrose and kept overnight at 4 °C. The tissue samples were 
mounted on a metal chuck using Lipshaw M-1 embedding matrix (Pittsburgh, USA) 
and rapidly frozen by quenching in liquid nitrogen. Coronal sections of 30 µm 
thickness were cut using a cryostat (Leica CM 3050). The sections were 
subsequently collected for free-floating immunofluorescence staining. 
 
4.3. Histochemistry 
4.3.1. Nissl staining with cresyl fast violet (CFV) 
         0.25 % CFV stock solution: 
                                             Cresyl Fast Violet (GURR’S, UK) 0.25 g 
                                              Deionised water 100 ml 
 
          CFV staining solution: 
                                        One part of 0.25 % CFV stock solution 





        Free floating sections of the hippocampus were mounted on gelatinized slide. 
After dry, they were immersed in CFV staining solution at 60 °C oven for 10 
minutes, followed by differentiation in 70 % ethanol. The sections were dehydrated 
in an ascending series of ethanol and cleared with xylene before being coverslipped 
with Permount as a mountant.  
 
4.3.2. Methyl green staining 
          0.25% methyl green Staining solution: 
                             Methyl green (GURR’S, UK) 0.25 g 
                             0.1 M acetate buffer (pH 4.8) 100 ml 
 
Procedures: 
        Free floating sections of the hippocampus were mounted on gelatinized slide 
and air-dried. After a brief dip in 0.1M acetate buffer (pH 4.8), the sections were 
immersed in methyl green staining solution for  approximately 30 seconds, followed 
by rinse in deionized water. The sections were then dehydrated in an ascending 
series of ethanol and cleared with xylene before being coverslipped with Permount 





5.1. Immunoperoxidase staining 
Antibodies: 
            Affinity-purified rabbit polyclonal antibodies to GABA transporter GAT-1, 
GAT-2, GAT-3 and BGT-1 were purchased from Chemicon (Chemicon). The 
antibody to GAT-1 was raised against amino acid residues 588-599 of rat GAT-1, 
and has been shown to detect a single band at 60 kDa in rat cortex (Ong et al., 1998). 
The antibody to GAT-2 was raised against the carboxyl terminus (amino acid 
residues 593-602) of GAT-2, and had been shown to have no cross-reactivity to the 
C-termini of other transmitter transporters. The antibody to GAT-3 was raised 
against the carboxyl terminus (amino acid residues 606-677) of GAT-3 and had been 
shown not to react with the C-termini of other transmitter transporters (Johnson et al., 
1996). The antibody to BGT-1 was raised against the carboxyl terminus (amino acid 
residues 600-614) of BGT-1 and does not react with the C-termini of other 
neurotransmitter transporters. It has been characterized in U373 MG human 
astrocytoma cells (Ruiz-Tachiquin et al., 2002). 
 
Procedures: 
(1) Free-floating sections were washed for 3 hrs in phosphate-buffered saline (PBS) 
at 10 minutes intervals to remove traces of fixative. 
                  0.1 M PBS (pH 7.4) 
                              Di-sodium hydrogen phosphate heptahydrate              26.8 g 
                              Sodium chloride 8.5 g 
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                              Distilled water 1000 ml 
(2) The sections were incubated for 1 hour in a solution of 5% goat serum (Vector, 
Burlingame, USA) to block non-specific binding of the antibody. 
(3) They were incubated overnight in an affinity- purified rabbit polyclonal antibody 
to BGT-1 (Chemicon, diluted 4 µg/ml in PBS).  
(4) The sections were washed in three changes of PBS at 10 minutes each. 
(5) The sections were incubated for 1 hour at room temperature in a 1:200 dilution 
of biotinylated goat anti-rabbit IgG (Vector). This was followed by three changes of 
PBS to remove unreacted secondary antibody. 
(6) The sections were reacted for 1 hour at room temperature with an avidin-
biotinylated horseradish peroxidase complex (Vector). 
(7) This was followed by wash in two changes (10 minutes each) of PBS, followed 
by incubation for 10 minutes in 0.2% nickel chloride solution in 0.1 M Tris buffer 
(TBS, pH 7.6). 
     0.1 M TBS: (pH 7.6) 
                   Tris base (Trihydroxymethylaminomethane)              6.0 g 
                    Sodium chloride            8.5 g 
                    Distilled water                                                            1000 ml 
(8) The reaction was visualised by treatment for 5 minutes in 0.05% 3, 3, 
diaminobenzidine   tetrahydrochloride (DAB) solution in Tris buffer containing 
0.05% hydrogen peroxide. The color reaction was stopped with several washes of 
Tris buffer, followed by PBS. Some of the sections were mounted on gelatine-coated 
glass slides, dehydrated, and lightly counterstained with methyl green before 
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coverslipping, while the remainders were processed for electron microscopy. 
Control sections were incubated with PBS or pre-immune rabbit serum instead of 
primary antibody. These showed absence of immunostaining. 
 
5.2. Cell counts 
      The number of BGT-1 positive glial cells in field CA1/CA3 of the hippocampus 
and the fimbria were manually counted using a light microscope. The counts were 
conducted in a “blind” manner at 200X magnification with the help of a grid. An 
area totaling 200 x 300 µm in each section, and four sections from each rat, were 
analysed. The mean and standard error was then calculated for each group of rats, at 
each time interval after kainate injection, and the results subjected to statistical 
analysis.  
 
5.3. Immunogold staining 
Procedures: 
(1) Sections intended for immunogold detection were washed in PBS (10 minutes x 
6), and then washed in Buffer A for 1 hour (10 minutes x 6). 
                              Buffer A: 
                                      Normal goat serum                                       1 ml 
                                      BSA                                                               1 g 
                                      Sodium azide                                                 0.1 g 
                                      Tween 20                                                       0.1 ml 
                                      0.1 M PBS                                               100 ml pH 8.2 
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(2) Sections were incubated overnight with antibody to BGT-1 (Chemicon diluted 4 
µg/ml in Buffer A) at room temperature with gentle shaking. 
(3) After washing for 1 hour (5 minutes x 12) in Buffer A, the sections were reacted 
for 4 hours at room temperature with goat anti-rabbit IgG conjugated to 1 nm gold 
particles (British BioCell, Cardiff, UK, diluted 1:200).  
(4) The sections were washed in Buffer A for 30 minutes and then in PBS for 30 
minutes with gentle agitation to remove excess gold conjugate. 
(5) They were fixed in 1% glutaraldehyde for 10 min to strengthen antibody binding 
to the tissue, and washed thoroughly in distilled water for 30 minutes while agitating 
to remove excess aldehyde and PBS. 
(6) The sections were mounted on clean glass slides and the area surrounding the 
specimen was dried. 
(7) The sections were immersed in fresh silver enhancement solution. The 
development was monitored using a microscope. 
(8) The sections were washed thoroughly in distilled water to stop the reaction. 
(9) Some of the sections were mounted on gelatinized slides, dehydrated, and 
coverslipped, while others were processed for electron microscopy. Control sections 
were incubated with PBS or preimmune rabbit serum instead of primary antibody. 






 5.4. Double immunofluorescence labelling 
        Sections were processed for free-floating immunofluorescence staining. They 
were incubated in blocking solution composed of 5% goat serum (Vector) and 0.1% 
Triton X-100 for 1 hour, followed by incubation with rabbit polyclonal antibody to 
BGT-1 (Chemicon, diluted 4 µg/ml in PBS) and mouse monoclonal antibody to glial 
fibrillary acidic protein (GFAP) (Chemicon, diluted 1 µg/ml in PBS) overnight. The 
sections were then washed three times in PBS, and incubated for 1 hour at room 
temperature in 1:200 dilution of FITC-conjugated goat anti-mouse IgG, and Cy3-
conjugated goat anti-rabbit IgG (Chemicon). The sections were mounted and 
examined using an Olympus FluoView FV500 confocal microscope. Control 
sections were incubated with PBS instead of primary antibodies. These showed 
absence of staining. 
 
6. Electron microscopy 
Procedures: 
(1) Electron microscopy was carried out by subdissecting the immunoperoxidase or 
immunogold stained sections into smaller rectangular portions that included the 
cerebral neocortex, or the CA fields / dentate gyrus of the hippocampus. The blocks 
were osmicated for 1 hour in a solution consisting of: 
                  1% osmium tetroxide (OsO4) 




 (2) They were dehydrated in an ascending series of ethanol and acetone as follows: 
                                        PBS                                        5 minutes 
                                        25% ethanol                           3 minutes 
                                        50% ethanol                           5 minutes 
                                        75% ethanol                           5 minutes 
                                        95% ethanol                           5 minutes 
                                        100% ethanol                         5 minutes 
                                         100% acetone                        5 minutes x 2 
 (3) The tissue blocks were infiltrated as follows: 
                100% acetone:Araldite (1:1)            10 minutes at room temperature 
                100% acetone:Araldite (1:4)             20 minutes at room temperature 
                1st change of fresh Araldite              45 minutes at 40 °C in oven 
                 2nd change of fresh Araldite            30 minutes at 50 °C in oven 
                 3rd change of fresh Araldite             30 minutes at 55 °C in oven 
  (4) They were flat embedded in fresh Araldite between transparent sheets at 60 °C 
for 24 hours in an oven.  
  (5) Ultrathin sections were obtained from the first 5 µm of the sections, mounted 
on 150-meshed copper grids coated with 0.3% Formvar, and stained with lead citrate, 
which is prepared as follows: 
                           0.3% Formvar solution: 
                                      Formvar 0.3 mg 
                                      Chloroform     100 ml 
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                             Lead citrate: 
                                       Lead nitrate                     1.33 g 
                                       Sodium citrate                 1.76 g 
                                       Distilled water                  30 ml 
                    The pH value of lead citrate was adjusted to 12 and the volume to 50 ml. 
 (6) They were viewed using a Philips EM208 or a Jeol 1010EX electron microscope.  
 
7. Cell culture of human U373 MG astrocytoma 
       Human U373 MG astrocytoma cells were obtained from ECACC (European 
collection of cell cultures). The cells were cultured in 75 cm2 culture flasks with 
medium containing Dulbecco's modified Eagle's medium (DMEM)/nutrient mixture 
F12 (Invitrogen, Carlsbad, USA) and 10% FCS (Hyclone, Logan, USA). Cells were 
grown as monolayers at 37 °C in 5% CO2. When they had reached approximately 
90% confluence, the cells were sub-cultured (1:3) after treatment with trypsin / 
EDTA (Invitrogen). U373 MG cells were plated in 24-well cell culture plates at a 
density of approximately 0.7 x 105 cells/ml, and were used when the cells had 
reached approximately 80% confluence. The cells were incubated with culture 
media containing 1 mM, 10 mM or 100 mM betaine or 1 mM, 10 mM or 100 mM 
sucrose for 12 hours. The osmolarities of sample betaine or sucrose solutions were 
measured using a vapor pressure osmometer (Wescor, Logan, USA), and were found 
to be 309 mmol/kg for control medium without addition of betaine or sucrose, 309, 
323, and 421 mmol/kg for media containing 1 mM, 10 mM, and 100 mM betaine 
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respectively; and 309, 324, and 420 mmol/kg for media containing 1 mM, 10 mM, 
and 100 mM sucrose respectively, i.e. the osmolarities were the same for equal 
concentrations of betaine or sucrose. 
 
8. Reverse transcription polymerase chain reaction (RT-PCR) 
Procedures: 
(1) Total RNA was extracted from human U373 MG astrocytoma cells using 
RNeasy Mini Kit (Qiagen, Valencia, USA) according to the manufacture’s 
instructions. After washed with PBS, cells were directly immersed in 600 µl of 
Buffer RLT (provided with the kit, containing a highly denaturing guanidinium 
isothiocyanate which immediately inactivates RNase).  
(2) Cells were scraped and passed through a 23-gauge needle for three times.  
(3) The clear lysate was transferred to microtube and mixed well with 600 µl of 70% 
ethanol. The resulted mixture was applied to an RNeasy mini spin column, 
centrifuged for 15 seconds at 10,000g.  During this step, the total RNA binds to the 
membrane.  
(4) The bound RNA was washed with buffer RW1 and RPE sequentially.  
(5) High-quality RNA was then eluted in 20 µl of RNase free water. RNA amount 
was determined spectrophotometrically.  
(6) To further eliminate the residue genomic DNA, the extracted RNA was digested 
with TURBO DNase (Ambion, Austin, USA).  
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(7) Reverse transcription (RT) was performed using Enhanced Avian RT First 
Strand Synthesis Kit (Sigma, St. Louis, USA). First strand cDNA was synthesized in 
a 50 µl reaction mixture containing 2 µg RNA, reverse transcriptase, oligo dT23 and 
RNase inhibitor. This was carried out by incubation at 52 °C for 50 minutes.   
(8)The synthesized cDNA was purified by equal mixture of phenol and CIA 
(chloroform: isoamyl alcohol, 24:1), followed by precipitation with absolute alcohol.  
After rinsed with 70% alcohol, cDNA was dissolved in 15 µl MilliQ water.  
(9) PCR was performed on an Omn-E hybaid thermocycler using Taq DNA 
polymerase. The BGT-1 specific primers used were as follows: sense 5’ -CAT CCT 
CAC CAT CGC CGT CAT-3’, antisense 5’-ACG CAG ACG CTT CCT GAA 
AGG-3’ (Borden et al., 1995a). 2 µl cDNA was amplified in 40 µl final volume 
containing PCR buffer, MgCl2, 0.25 mM of each dNTP and 2U of Taq DNA 
polymerase. The following PCR cycling parameters were used: denaturation at 95 
°C for 3 minute, 35 cycles with denaturation at 95 °C for 1 minute, annealing at 60 
°C for 15 seconds and extension at 72 °C for 1 minute and 20 seconds, followed by 
one additional extension cycle at 72 °C for 15 minutes.  
(10) The resulted PCR products were electrophoresized in 1.5% agarose gel, excised 
from the gel and eluted into 20 µl buffer using QIAquick Gel Extraction Kit 
(Qiagen).  
(11) The PCR products were then cloned into plasmid vector using TOPO TA 
Cloning Kit (Invitrogen) according to the manufacture’s instructions. The PCR 
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products were first incubated with TOPO vector at room temperature for 5 minutes. 
This was followed by chemical transformation into “One Shot” Competent Cells.  
(12) The next day, white colonies on agar plates were picked and grown in SOC 
medium (2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 10 mM MgSO4, 20 mM glucose, 30 µg/ml kanamycin).  
(13) After analyzed by PCR and EcoR Ι digestion, the extracted plasmids inserted 
with BGT-1 sequence were bidirectionally sequenced using ABI 7300 (Perkin-
Elmer, Wellesley, USA) to verify its authenticity. 
 
9. Cell immunofluorescence confocal microscopy 
       Human U373 MG cells were plated at equal density on polylysine-coated glass 
coverslips in 24-well plates. After attachment, cells were incubated with culture 
medium containing betaine or sucrose for 12 hours. Cells were then washed twice in 
PBS and fixed in 4% paraformaldehyde for 20 minutes at room temperature. 
Following washes in PBS, cells were incubated in blocking solution composed of 
5% normal goat serum (Vector) and 0.1% Trition X-100 in PBS for 1 hour. 
Coverslips were then incubated overnight at 4 °C in an affinity-purified rabbit 
polyclonal antibody to BGT-1 (Chemicon, diluted 4 µg/ml in PBS). After three 
rinses with PBS, coverslips were incubated for 1 hour in a 1:200 Cy3-conjugaed 
goat anti-rabbit IgG (Chemicon). This was followed by three washes of PBS to 
remove the unreacted antibody. Coverslips were then reacted for 3 minutes at room 
temperature with DAPI solution (Molecular Probes, Eugene, USA). Coverslips were 
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mounted on glass slides and examined using an Olympus FluoView FV500 confocal 
microscopy. Images were obtained through the center of the cell by examining DAPI 
nuclear staining. Controls were incubated with PBS or preimmune rabbit serum 
instead of primary antibodies.  
 
10. Cell-ELISA 
        Human U373 MG cells were plated at equal density in 24-well plates. After 
attachment, cells were incubated with culture medium containing betaine or sucrose 
for 12 hours. Cells were then washed twice in PBS and fixed in 4% 
paraformaldehyde in 50 mM phosphate buffer, pH 7.4, for 20 min at room 
temperature. The paraformaldehyde was removed and treated with 95% ethanol for 
1 min, followed by air drying. After washed three times with PBS, cells were 
incubated with 3% H2O2 in PBS for 5 min to minimize endogenous peroxidase 
activity. Cells were incubated with blocking solution composed of 5% normal goat 
serum (Vector) and 0.1% Trition X-100 in PBS for 1 hour, and then incubated with 
primary antibodies against BGT-1 (Chemicon) overnight at 4 °C. Cells were washed 
four times with PBS, incubated with a 1:2000 anti-rabbit peroxidase-conjugated 
secondary antibody (Amersham Biosciences) for 1 hour at room temperature, and 
washed five times in PBS. Samples in each well were incubated with 250 µl of 
Enhanced K-Blue substrate (Neogen, Lexington, USA) for 10 min, after which the 
colored reaction end product was terminated with the Redstop solution (Neogen). 
The optical density of samples was determined at 650 nm. Control experiments with 
PBS were included to determine background value, which was subtracted from the 
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OD650 readings. In order to normalize the reaction to the number of cells in each 
well, cell quantification assay was performed. After the incubation with Enhanced 
K-Blue substrate, the cells were washed twice with PBS and twice with deionized 
water. After drying the wells for 5 min, 200 µl of crystal violet solution [0.04% 
crystal violet in 4% (v/v) ethanol] was added for 30 min at room temperature. Cells 
were washed four times with deionized water and 200 µl of 1% SDS solution was 
added and incubated on a shaker for 1 h at room temperature. The optical density 
was measured at 595 nm. The OD650 value of the ELISA reaction was normalized to 
the OD595 value obtained from the cell quantification assay to give the normalized 
value of the ELISA reaction. For each experiment four parallel samples were used.  
 
11. [14C] betaine uptake assay 
        Uptake assay was carried out using methods described previously (Ruiz-
Tachiquin et al., 2002) with minor modifications. Human U373 MG cells were 
plated at equal density in 24-well plates. After attachment, cells were incubated with 
culture medium containing betaine or sucrose for 12 hours. The culture medium was 
washed twice with prewarmed HEPES-buffered Krebs (KH) medium (in mM: 
HEPES 20, NaCl 130, KCl 3.7, CaCl2 1.8, MgSO4 1.18,  K2HPO4 1.8, glucose 11, 
pH 7.4) and then incubated in 500 µl KH medium containing 0.3 µCi [14C]  betaine 
(American Radiolabelled Chemicals, St., Louis, USA) for 30 minutes at 37 °C. The 
medium was removed by aspiration, and the monolayers were thoroughly washed 
with ice-cold KH buffer and solubilized with 0.5 ml 1% SDS. Aliquots of the 
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suspension were used for liquid scintillation counting by a liquid scintillation 
counter (Model LS 6800, Beckman-Coulter, Fullerton, USA). The protein content of 
each well was determined using BCA protein assay (Pierce), and the normalized 
count calculated by dividing the scintillation count by the protein concentration of 
each well. For each experiment four parallel samples were used.  
 
12. Statistics 
       All data were expressed as mean ± SEM, and subjected to statistical analysis 
using one-way analysis of variance (ANOVA) followed by post hoc Bonferroni’s 
test or Student’s t-test when appropriate. P values < 0.05 were considered 




















1. Distribution and subcellular localization of betaine/GABA transporter in the 
monkey cerebral neocortex and hippocampus 
1.1. Specificity of antibody 
        The affinity purified polyclonal antibody to BGT-1 detected a major band at 
approximately 60 kDa in homogenates of the monkey liver, a result consistent with 
the findings of Ruiz-Tachiquin et al. in human astrocytoma cells (Ruiz-Tachiquin et 
al., 2002), but two bands at 60 kDa and 65 kDa in homogenates from the monkey 
neocortex. The extracellular loops of BGT-1 between transmembrane domains 3 and 
4 contain potential sites for N-glycosylation, and the higher molecular weight band 
is likely a glycosylated form of BGT-1 (Fig. 3). 
 
1.2. Light microscopy 
1.2.1. Cerebral neocortex  
       The cerebral cortex was, in general, lightly labelled for BGT-1. Light staining 
was observed in layers III (Fig. 4A), V and VI (Fig. 4B) of the cortex, whilst layer 
IV was almost unstained. Immunoreactivity was observed on cell bodies, 
particularly in the superficial portion of layer III (Fig. 4A). An apical dendrite could 
be discerned on most of the labelled cell bodies, and the later were therefore 
identified as pyramidal neurons (Fig. 4A, B). Large numbers of dendrites were also 
observed in the neuropil (Fig. 4A, B). Immunoreactivity was not observed in glial 





        The hippocampus was more densely labelled for BGT-1 than the cortex. 
Moderately densely labelled pyramidal cell bodies, and many labelled dendrites 
were observed. The cell bodies and dendrites of CA1 neurons (Fig. 4C) were more 
distinctly labelled than those in CA3 (Fig. 4D). The stratum lucidum of CA3, 
containing the axons of dentate granule neurons, appeared mostly unlabelled (Fig. 
4D). The cell bodies of dentate granule neurons were also very lightly labelled or 
unlabelled. 
 
1.3. Electron microscopy 
       Immunoperoxidase labelling was observed in the cell bodies and dendrites of 
pyramidal neurons in the cortex and hippocampus. The labelled neurons contained 
nuclei with light heterochromatin clumps and cytoplasm with short cisternae of 
endoplasmic reticulum and features of pyramidal neurons (Feldman, 1984) (Fig. 5A). 
Neurons with dense heterochromatin clumps in the nucleus, and features of non-
pyramidal neurons were unlabelled. Label was also absent from glial cells bodies, 
including astrocytes and oligodendrocyte-like cells, and astrocytic end feet around 
blood vessels. Large numbers of immunolabelled dendrites or dendritic spines were 
observed in the neuropil. The immunolabelled dendrites were of small diameter (less 
than 1 µm). In contrast, larger diameter dendritic shafts were unlabelled or poorly 
labelled. The immunolabelled dendritic spines formed asymmetrical synapses with 
unlabelled axon terminals, containing small round vesicles. Immunoperoxidase 
reaction product was observed in the cytosol of the dendrites, or the ‘extra-
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perisynaptic’ region of the cell membranes of the dendrites, i.e. regions away from 
the synaptic clefts or the perisynaptic area (Fig. 5B). 
       A similar pattern of staining was observed in the immunogold labelled sections. 
As in the immunoperoxidase stained sections, label was observed in the cytoplasm 
of cell bodies of pyramidal neurons (Fig. 6A), and in the cytosol or ‘extra-
perisynaptic’ region of the cell membranes of small diameter dendrites or dendritic 
spines (Fig. 6B, C). 
 
2. Changes in the expression of GABA transporters in the rat hippocampus 
after kainate induced neuronal injury  
2.1. Western blot analysis 
       The affinity purified polyclonal antibody to BGT-1 detected a major band at 
approximately 60 kDa, a result consistent with the findings of Ruiz-Tachiquin et al. 
(Ruiz-Tachiquin et al., 2002), in the rat liver, but a 60 kDa and a 65 kDa band in 
both normal, and kainate-injected rat hippocampus. The extracellular loops of BGT-
1 between transmembrane domains 3 and 4 contain potential sites for N-
glycosylation, and the higher molecular weight band is most likely a glycosylated 
product of BGT-1 (Fig. 7). 
 
2.2. Light microscopy 
2.2.1. CA fields of normal or saline-injected rats 
         GAT-1 labelling was observed as a fine reticular network, around the 
unlabelled cell bodies in the CA fields (Fig. 8A). In contrast to GAT-1, very little or 
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no staining for GAT-2 was observed (Fig. 8B). GAT-3 labelling was observed in 
occasional glial cell bodies, but in a dense meshwork of fine processes in the 
neuropil (Fig. 8C). Light BGT-1 labelling was observed in cell bodies of pyramidal 
neurons and in the neuropil (Fig. 8D). 
             
2.2.2. Three days after kainate injections 
      Loss of neurons was observed in Nissl stained sections mainly in field CA3 (Fig. 
9A), but also in CA1 on the side ipsilateral to the kainate injection. Cell loss was 
also observed, but was less extensive, in the CA fields of the contralateral 
hippocampus. No obvious loss of neurons was observed in the dentate gyrus. A 
decrease in GAT-1 (Fig. 9B) and GAT-3 (Fig. 9C) staining was observed in the CA 
fields affected by the kainate injection, compared to that of saline-injected rats. No 
increase or decrease in immunostaining for GAT-2 was observed (data not shown). 
Loss of BGT-1 immunoreactivity was observed in cell bodies and dendrites of 
pyramidal neurons, but increased BGT-1 immunoreactivity was observed in a 
population of glial cells in the degenerating CA fields (Fig. 9D, 12). No change in 
GAT-1, GAT-3, or BGT-1 expression was observed in the dentate gyrus, compared 
to that in control rats. 
            
2.2.3. One week after kainate injections 
     CA3 or CA1 fields affected by kainate showed a loss of neurons, but an increase 
in glial cell number in Nissl stained sections (Fig. 10A). As in the 3 day post-kainate 
injected rats, a decrease in GAT-1 (Fig. 10B) and GAT-3 (Fig. 10C) labelling, and 
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no change in GAT-2 labelling (data not shown) was observed in CA fields of 
kainate-injected rats. A further increase in BGT-1 immunoreactivity was observed in 
glial cells in the degenerating CA fields (Fig. 10D). ANOVA statistics showed a 
significant increase in the number of BGT-1 positive glial cells (Fig. 12). Labelling 
was observed on the cell bodies (Fig. 10D) and end-feet around blood vessels. Under 
electron microscopy, labelled cells exhibited morphological features of astrocytes 
and were doubled labelled for GFAP, an astrocytic marker (see below). No change 
in GAT-1, GAT-3, or BGT-1 expression was observed in the dentate gyrus, 
compared to that in control rats. 
 
2.2.4. Three weeks after kainate injections 
      Very little GAT-1, GAT-2 and GAT-3 staining was observed in the lesioned CA 
fields at 3 weeks post-kainate injection (Fig. 11A). The density of BGT-1 staining 
(Fig. 11B) was also reduced, compared to the 1 week post-kainate injected rats, and 
the number of BGT-1 positive glial cells was significantly less than that at 1 week 
post-kainate injection (Fig. 11B), as further revealed by ANOVA statistics (Fig. 12). 
No change in GAT-1, GAT-3, or BGT-1 expression was observed in the dentate 
gyrus. 
 
2.3. Electron microscopy 
       Electron microscopy showed that BGT-1 positive glial cells in the lesioned CA 
fields had large cell bodies with irregular cell outlines. The nucleus contained evenly 
dispersed fine heterochromatin clumps, and absence of marginated heterochromatin 
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on the inner aspect of the nuclear envelope. The cytoplasm contained dense bundles 
of glial filaments. They thus had features of astrocytes (Fig. 11C). 
 
2.4. Double immunofluorescence labelling for BGT-1 and GFAP 
      The untreated hippocampus, or the unlesioned CA fields of the kainate injected 
hippocampus (Fig 13A, B), showed BGT-1 labelling in the cell bodies and dendrites 
of pyramidal neurons in the CA fields. In contrast, areas affected by neuronal loss 
after kainate injection showed loss of BGT-1 labelling in the stratum pyramidale, 
consistent with loss of pyramidal neurons, but a large increase in number of BGT-1 
labelled glial cells. The latter were double labelled for GFAP, confirming that there 
were astrocytes (Fig. 13C, D). 
 
3. Differential effects of betaine and sucrose on BGT-1 expression and betaine 
transport in human U373 MG astrocytoma cells and rat hippocampal 
astrocytes 
3.1. Reverse transcription polymerase chain reaction (RT-PCR) 
        RT-PCR detected a sharp band of the predicted size in human U373 MG 
astrocytoma cells using BGT-1 specific primer (Fig. 14), a result consistent with the 
findings of Ruiz-Tachiquin et al. (Ruiz-Tachiquin et al., 2002). The amplified cDNA 
segment of BGT-1 was subsequently cloned and bidirectionally sequenced to 
confirm its sequence. These data, together with the following results of cell ELISA 
and immunofluorescence confocal microscopy indicate that human U373 MG 
astrocytoma cells endogenously express the betaine/GABA transporter BGT-1. 
 87
3.2. Cell ELISA 
       U373 MG astrocytoma cells that had been incubated for 12 hours with 1mM, 10 
mM and 100 mM betaine showed 20%, 36% and 95% increases in BGT-1 
immunointensity, compared to controls incubated with media without additional 
betaine or sucrose. These increases were statistically significant. 
       In contrast, cells that had been incubated for 12 hours with 1mM, 10 mM and 
100 mM sucrose showed no significant increases in BGT-1, compared to controls 
(Table 1). 
 
3.3. Immunofluorescence confocal microscopy 
       U373 MG astrocytoma cells that had been incubated for 12 hours with 1mM, 10 
mM and 100 mM betaine showed increases in BGT-1 immunoreactivity, compared 
to controls incubated with media without additional betaine or sucrose. The 
increased immunolabelling was present as punctate structures in the cell bodies of 
the astrocytes, as well as on the cell membrane (Fig. 15A-E). 
       In contrast to cells that had been incubated with betaine, cells that had been 
incubated for 12 hours with 1mM, 10 mM and 100 mM sucrose showed no obvious 
increases in BGT-1 immunoreactivity, compared to controls (Fig. 15F, G, H). 
 
3.4. [14C] betaine uptake assay 
        Astrocytoma cells that had been incubated for 12 hours with 1mM, 10 mM and 
100 mM betaine showed 13%, 37% and 50% increases in [14C] betaine uptake, 
compared to controls. These increases were statistically significant. 
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       In contrast to cells that had been incubated with 1mM and 10mM betaine, cells 
that had been incubated for 12 hours with 1 mM and 10 mM sucrose showed no 
significant increases in [14C] betaine uptake. A rather unexpected and marked (123%) 
increase in betaine uptake was, however, observed in cells incubated with 100 mM 
sucrose compared to controls (Table 2). 
 
3.5. Light microscopy revealed by immunoperoxidase labelling for BGT-1 
      In rats that had been injected with kainate plus saline, loss of BGT-1 
immunoreactivity in pyramidal neurons was accompanied by increased BGT-1 
immunoreactivity in only a few glial cells in the degenerating CA field (Fig. 16A, B, 
Table. 3). In contrast, rats that had been injected with kainate plus betaine showed a 
marked induction of BGT-1 immunoreactivity in glial cells in the degenerating CA3 
and the adjacent fimbria (Fig. 16C, 2F, Table. 3). The glial cells had features of 
astrocytes (see below). 
 
3.6. Double immunofluorescence labelling for BGT-1 and GFAP 
      As with the immunoperoxidase stained sections, few glial cells were observed in 
the degenerating CA fields and fimbria in the rats that had received kainate and 
saline injections (Fig. 17A, B). In contrast, large numbers of glial cells were 
observed in these regions, in rats that were injected with kainate plus betaine (Fig. 
17C, D). The BGT-1 positive cells were double labelled for GFAP, confirming that 
they were astrocytes. 
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3.7. Electron microscopy 
       Electron microscopy revealed that BGT-1 positive glial cells in the degenerating 
CA fields and the adjacent fimbria areas had large cell bodies with irregular cell 
outlines. The cytoplasm contained bundles of glial filaments, and the nucleus 
contained evenly dispersed fine heterochromatin clumps. They thus had 
morphological features of astrocytes (Fig. 18). The astrocytes in rats that received 
kainate plus saline showed non-bloated mitochondria with closely packed cristae 
(Fig. 18A, B). In contrast, large numbers of swollen mitochondria were observed in 
astrocytes in the degenerating CA3 of rats that had been injected with kainate plus 



















1. Distribution and subcellular localization of betaine/GABA transporter BGT-
1 in the cerebral neocortex and hippocampus 
1.1. Distribution of BGT-1 in cerebral neocortex and hippocampus 
       BGT-1 was observed in pyramidal neurons in the cerebral neocortex and the CA 
fields of the hippocampus. Large numbers of small diameter dendrites or dendritic 
spines were observed in the neuropil. This distribution of BGT-1 is different from 
that of two other GABA transporters, GAT-1 and GAT-3. GAT-1 is exclusively 
expressed in axon terminals that formed symmetrical synapses in the human and 
monkey cerebral cortex and the monkey basal ganglia, although it can also be 
expressed in astrocytes in the rat cortex (Ong et al., 1998; Minelli et al., 1995). 
GAT-3 expression is low in the cortex and hippocampus, but been localized to 
astrocytic processes, in the monkey and rat basal ganglia and brainstem (Ng et al., 
2000; Ng and Ong, 2001). GAT-2 is localized mostly in leptomeninges (pia and 
arachnoid) surrounding the brain (Conti et al., 1999). 
      The localization of BGT-1 in dendritic spines of pyramidal neurons is consistent 
with the results of previous cell culture studies. MDCK cells stably transfected with 
mRNAs to BGT-1 or GAT-1 showed that the BGT-1 was localized to the basolateral 
membrane, consistent with a dendritic localization, whereas GAT-1 was localized to 






1.2. Subcellular localization of BGT-1 revealed by electron microscopy 
        The immunolabelled small diameter dendrites or dendritic spines made 
asymmetrical synaptic contacts with unlabelled axon terminals containing small 
round vesicles, characteristic of glutamatergic terminals. BGT-1 label was observed 
in an extra-perisynaptic region, away from the post-synaptic density. 
Immunoreactivity was not observed in portions of dendrites that formed symmetrical 
synapses, axon terminals, or glial cells. 
 
1.3. Functional implication of BGT-1 in osmoregulation in the central nervous 
system 
       The distribution of BGT-1 on dendritic spines, rather than at GABAergic axon 
terminals, suggests that the transporter is unlikely to play a major role in terminating 
the action of GABA at a synapse. It may, however, serve to sequester GABA that 
has diffused away from synaptic regions, thereby assuring the fidelity of 
transmission, as suggested previously (Borden, 1996). Any GABA taken up is 
probably broken down. A previous study has shown elevated expression of GABA 
transaminase, an enzyme important in breakdown of GABA, in hippocampal 
pyramidal neurons after ischemia-reperfusion injury (Kang et al., 2001). 
       The osmolyte betaine is more likely to be the physiological substrate of BGT-1 
in the brain. BGT-1 transports GABA with a Km of approximately 20-100 µM, but 
betaine with a Km of approximately 200-400 µM (Chen et al., 2004). BGT-1 
displays a relatively high degree of sequence identity with the transporter for taurine 
(Smith et al., 1992), a major osmoregulator in the central nervous system. Betaine is 
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used as a non-perturbing osmolyte by plants, bacteria, invertebrates and vertebrates 
to compensate for hypertonic stress (Yancey et al., 1982; Burg 1995). In vertebrates, 
betaine transport requires Na+ and Cl- and is modulated by changes in osmolarity 
(Nakanishi et al., 1990). Betaine has been detected in the brain, and its levels are 
increased following salt loading (Heilig et al., 1989), consistent with a role in 
osmoregulation. High levels of betaine have been detected in single neurons isolated 
from the abdominal ganglion from Aplysia californica using the technique of nuclear 
magnetic resonance (NMR) spectroscopy (Grant et al., 2000). The presence of BGT-
1 in pyramidal neurons therefore suggests that these neurons are likely to utilize 
betaine to maintain osmolarity. It is postulated that maintenance of osmolarity and 
prevention of cell shrinkage could be critical to the proper structure and function of 
proteins on the cell membranes of the neurons.  
 
2. Changes in the expression of GABA transporters in the rat hippocampus 
after kainate induced neuronal injury 
2.1. Decrease in the expression of GAT-1 after kainate induced neuronal injury  
      In normal rats, GAT-1 labelling was observed as a fine reticular network, around 
the unlabelled cell bodies of pyramidal neurons in the CA fields. A decrease in 
GAT-1 immunostaining was observed in the degenerating CA subfields. The 
decreased GAT-1 staining could be due either to downregulation of the transporter 




2.2. Decrease in the expression of GAT-3 after kainate induced neuronal injury  
       GAT-3 staining was observed in occasional glial cell bodies, and a meshwork of 
fine processes in the neuropil in normal rats. A decrease in GAT-3 immunostaining 
was observed in the degenerating CA subfields. The decreased GAT-3 staining is 
more likely due to downregulation of the transporter by astrocytes, since BGT-1 
expression was concomitantly increased in these cells.  
       The observed localization of GAT-1, GAT-2 and GAT-3 in the CA fields of the 
normal rat hippocampus is in agreement with the previous reports on the rat brain 
(Ribak et al., 1996; Conti et al., 1999). The decrease in GAT-1 and GAT-3 staining 
in the lesioned CA3 field after kainate lesions might lead to decreased GABA uptake 
from the extracellular space. The decrease in GAT-1 and GAT-3 staining in the 
hippocampus after kainate treatment is consistent with previous findings of 
decreased GAT-1 and GAT-3 expression in the CA3 region of epilepsy patients with 
mesial temporal sclerosis (Mathern et al., 1999). 
 
2.3. Upregulation of BGT-1 in astrocytes after kainate induced neuronal injury 
      BGT-1 immunostaining was observed in cell bodies and apical dendrites of 
pyramidal neurons, a result consistent with that of the study on the monkey brain. In 
contrast, significantly increased BGT-1 immunoreactivity was observed in glial cells 
at 1 week after kainate injection. The BGT-1 immunoreactivity in glial cells 
declined at 3-week post-kainate injection. Labelled glial cells were found to have 
dense bundles of glial filaments characteristic of astrocytes at electron microscopy, 
and were double labelled for GFAP, a marker for astrocytes. Non-specific 
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immunostaining by BGT-1 antibody is unlikely, since a well-characterized antibody, 
supplied in the affinity-purified form, was used. Our Western immunoblot analyses 
on the rat liver also confirmed that the antibody detected a band at 60 kDa, 
consistent with the expected molecular weight of BGT-1. The higher molecular band 
at 65kDa observed in hippocampal homogenates likely represents a glycosylated 
form of BGT-1. The transporter is predicted to have two putative glycosylation sites 
in the extracellular loop between membrane-spanning domains 3 and 4 (Borden et 
al., 1995). 
      The increase in BGT-1 expression might lead to an increase in GABA uptake. 
This effect on GABA uptake is, however, likely to be small, since BGT-1 is a weak 
GABA transporter (Kwon, 1996). In view of the decreased expression of GAT-1 and 
GAT-3, it therefore seems unlikely that enhanced GABA uptake in the glial scar 
could be a factor in contributing to increased excitation of neurons in epilepsy. 
 
2.4. Role of BGT-1 in astrocytes in osmoregulation after kainate induced 
neuronal injury  
       The localization of BGT-1 in cell bodies and apical dendrites of pyramidal 
neurons suggests that neurons have the ability to concentrate betaine, and is 
consistent with the results of a recent study using single cell nuclear magnetic 
resonance imaging, which showed high levels (100-300 mM) of betaine in normal 
neuron (Grant et al. 2000). 
     Upregulated BGT-1 in astrocytes may play a role in osmoregulation of these cells. 
BGT-1 transports GABA with a Km of approximately 20-100 µM, but betaine with 
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a Km of approximately 200-400 µM (Kwon, 1996). Furthermore, BGT-1 exhibits 
relatively high (61%) sequence similarity to the transporter for taurine (Smith et al., 
1992), an important osmoregulator in the central nervous system. The response of 
BGT-1 to osmotic stress has been well studied, particularly in Madin-Darby canine 
kidney (MDCK) cells (Uchida et al., 1993a; Uchida et al., 1993b; Takenaka et al., 
1995), and cultured astrocytes (Bitoun and Tappaz, 2000b). Astrocytes respond to 
hyperosmotic stress by an initial shrinkage, followed by recovery of cell volume 
(Bitoun and Tappaz 2000b). The recovery of cell volume was enhanced by addition 
of an osmolyte, taurine, into the culture medium (Bitoun and Tappaz 2000b). The 
osmolytes taurine, sorbitol, myoinositol, and betaine accumulate in cells exposed to 
hypertonic stress, as a result of transcription of genes containing tonicity-responsive 
enhancer (TonE), which encode for proteins that catalyse the transport or synthesis 
of these osmolytes (Handler and Kwon, 2001). The BGT-1 gene contains a TonE 
(Takenaka et al., 1994) and increased BGT-1 mRNA has been observed in cultured 
astrocytes following hyperosmotic stress (Bitoun and Tappaz, 2000b). 
       Previous studies have revealed that osmotic overloading occurs following 
kainate-induced neuronal injury (Rothman et al., 1985; Olney et al., 1986; Hasbani 
et al., 1998; Al Noori et al., 2000). It is therefore possible that increased expression 
of BGT-1 in astrocytes after kainate treatment has a physiological role in enabling 
these cells to resist shrinkage caused by the hyperosmotic stress. Expression of 
genes encoding osmolyte transporters in astrocytes has been reported to be 
prolonged even after cell volume has recovered, probably due to the inertia of the 
transduction pathway (Bitoun and Tappaz, 2000b). It is therefore conceivable that 
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prolonged expression of BGT-1 in astrocytes could lead to excessive water influx, 
and swelling of these cells.  
 
3. Differential effects of betaine and sucrose on BGT-1 expression and betaine 
transport in human U373 MG astrocytoma cells and rat hippocampal 
astrocytes 
3.1. Effects of betaine or sucrose on BGT-1 expression in vitro 
      Treatment of cultured human U373 MG astrocytoma cells with betaine resulted 
in an increase in BGT-1 protein as detected by cell-ELISA analysis. A dose-
dependent effect on BGT-1 expression was observed. In comparison to betaine, 
isosmolar concentrations of sucrose had a lesser effect on BGT-1 induction, and did 
not significantly increase BGT-1 immuno-intensity under these conditions. 
       The effect of betaine on BGT-1 expression at the protein level was also studied 
by confocal microscopy. An increase in BGT-1 immunoreactivity was observed in 
cells treated with increasing concentrations of betaine, consistent with the findings 
of cell-ELISA. The BGT-1 was mostly present in the cytoplasm, but some 
immunoreactivity was found on the cell membrane, consistent with its function as an 
osmolyte transporter. 
 
3.2. Effects of betaine or sucrose on [14C] betaine uptake in vitro 
      Cultured human U373 MG astrocytoma cells that have been incubated with non-
radioactive labelled betaine for 12 hours showed increased transport of radioactive 
betaine with a similar dose-dependent manner. This finding is consistent with that of 
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the cell-ELISA and immunofluorescence findings, and shows that the betaine 
induced increases in BGT-1 expression is associated with increased transport of 
betaine. Consistent with the non-significant change in BGT-1 protein level after 
sucrose treatment, no significant increase in betaine transport was observed when 
cells were incubated with 1-10 mM of sucrose. Since the high concentrations of 
sucrose could mimic any non-specific forms of hyperosmotic stress, these findings 
could support the notion that betaine is a more effective inducer of BGT-1 
expression and activity, than other non-specific forms of osmotic stress. 
       In contrast to 1 mM and 10 mM sucrose, a marked increase in betaine uptake 
was observed when cells were incubated for 12 hours with 100 mM sucrose. This is 
despite the little or no induction in BGT-1 immunoreactivity, and suggests that the 
uptake is not mediated by BGT-1. It has been reported that in addition to BGT-1, 
betaine could be taken up by the "amino acid transport system A" under 
hyperosmotic conditions (Petronini et al., 1994). The activity of amino acid transport 
system A is induced by high concentrations of sucrose (Petronini et al., 2000). It is 
therefore possible that both BGT-1 and the amino acid transport system A might be 
involved in uptake of betaine in astrocytes - BGT-1 being specifically induced by 
betaine, and amino acid transport system A being non-specifically induced by very 
high levels of osmotic stress. 
 
3.3. Effects of betaine on BGT-1 expression in vivo  
       Betaine has been suggested as a protective osmolyte (Yancey et al., 1982; Burg, 
1995). This effect has been most extensively studied in kidney cells. In response to 
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hyperosmotic stress, cells increase the BGT-1 expression to increase betaine 
transport into the cytoplasm to counter the effect of hyperosmotic stress (Kwon and 
Handler, 1995; Kwon, 1996; Burg et al., 1997). The increase in BGT-1 expression 
by astrocytes may therefore be a protective mechanism that these cells use to 
counteract the effect of hyperosmotic stress induced after excitotoxic injury. On the 
other hand, prolonged and excessive induction of BGT-1 by astrocytes may result in 
an excessive betaine and water influx into the astrocytes and might be a factor in 
contributing to astrocytic swelling after excitotoxic injury. The mechanism by which 
betaine induces BGT-1 expression remains unknown. 
       The localization of BGT-1 in hippocampal neurons of the normal hippocampus 
suggests that these neurons contain high levels of betaine. In addition to being an 
osmolyte, betaine also functions as a donor of 1-carbon (methyl groups) to the 
methionine cycle, and is important in limiting the toxicity of homocysteine 
(reviewed in Craig, 2004). It is postulated that the betaine could be released into the 
extracellular space during neuronal injury. In order to determine whether betaine 
could induce astrocytic BGT-1 expression in vivo, we injected betaine into the 
cerebral ventricles of rats that have received an intracerebroventricular kainate 
injection one day earlier. We observed that there was a significant increase in BGT-
1 immunoreactivity in astrocytes in rats that receive kainate and betaine injections, 
compared to those that had received kainate and saline injections. The rats that had 
been treated with kainate and betaine also showed large number of swollen 
mitochondria in astrocytes, whereas such swollen mitochondria were not observed in 
the rats injected with kainate and saline. In this study, a dose of 10 µl of 100mM 
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betaine was injected into the cerebral ventricles to mimic betaine that could be 
released from neurons following such injury. Although no information exists as to 
the level of betaine in mammalian neurons, very high levels of betaine (100-300 
mM), has been observed in single neurons from the abdominal ganglion of the sea 
hare, Aplysia californica, using the technique of single neuron nuclear magnetic 
resonance spectroscopy (Grant et al., 2000). The betaine concentration in these 
neurons was approximately 9 fold greater than that of another osmolyte, taurine, in 
these neurons (Grant et al., 2000). The dose that we injected 
introcerebroventricularly may therefore not be excessive, and may therefore mimic a 
pathological condition whereby betaine is released from dying neurons. 
      In view of the above findings, we postulate that the release of betaine from dying 
neurons may be a factor in contributing to increase BGT-1 expression in astrocytes. 
This might contribute to astrocytic swelling following head injury or stroke. Further 
studies are necessary to study the mechanism by which betaine could induce BGT-1 




























        GABA transporters, termed GAT-1, GAT-2, GAT-3, and BGT-1 have been 
cloned and identified. They show approximately 50% amino acid sequence 
similarity, and belong to the family of Na+- and Cl--dependent neurotransmitter 
transporters with 12 putative transmembrane spanning domains. In contrast to GAT-
1, 2 or 3, the betaine/GABA transporter BGT-1 is capable of utilizing both GABA 
and betaine as substrates. BGT-1 has been extensively studied in MDCK cells, and it 
is responsible for the uptake of betaine into kidney cells when adapted to 
hyperosmotic environments. In addition to being a protective osmolyte, betaine can 
function as a methyl donor to detoxify the homocysteine.  
        The expressions of GAT-1, GAT-2 and GAT-3 in the brain have been studied 
by immunocytochemistry. In contrast, the distribution and subcellular localization of 
BGT-1 in the brain has yet to be determined. Therefore, this study employed 
immunocytochemistry and electron microscopy to elucidate the distribution and 
subcellular localization of BGT-1 in the cerebral neocortex and hippocampus. BGT-
1 was observed in pyramidal neurons in the cerebral neocortex and the CA fields of 
the hippocampus. Large numbers of small diameter dendrites or dendritic spines 
were observed in the neuropil. These made asymmetrical synaptic contacts with 
unlabelled axon terminals containing small round vesicles, characteristic of 
glutamatergic terminals. BGT-1 labelling was observed in an extra-perisynaptic 
region, away from the post-synaptic density. The distribution of BGT-1 on dendritic 
spines, rather than at GABAergic axon terminals, suggests that the transporter is 
unlikely to play a major role in terminating the action of GABA at a synapse. 
Instead, the osmolyte betaine is more likely to be the physiological substrate of 
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BGT-1 in the brain, and the presence of the transporter in pyramidal neurons 
suggests that these neurons utilize betaine to maintain osmolarity. 
       The functional role of BGT-1 in the brain has not been fully elucidated. BGT-1 
might contribute to osmoregulation in the brain, since betaine, a substrate for BGT-1, 
has been assigned a role in osmoregulation. Osmoregulation is critical for 
maintaining brain function. Osmotic stress has been shown in neuronal excitotoxcity. 
Since changes in expression of GABA transporters / BGT-1 might result in 
alterations in levels of GABA / betaine in the extracellular space, with consequent 
effects on neuronal excitability or osmolarity, this study investigated the expression 
of GABA transporters in the rat hippocampus, following kainate-induced neuronal 
injury. A decrease in GAT-1 and GAT-3 immunostaining, and no change in GAT-2 
staining, was observed in the degenerating CA subfields. In contrast, increased 
BGT-1 immunoreactivity was observed in astrocytes after kainate injection. BGT-1 
is a weak transporter of GABA in comparison to other GABA transporters, and the 
increased expression of BGT-1 in astrocytes might be a protective mechanism 
against increased osmotic stress known to occur after excitotoxic injury. On the 
other hand, excessive or prolonged BGT-1 expression might be a factor contributing 
to astrocytic swelling after brain injury. 
        BGT-1 expression has been studied in astrocytes at the mRNA level, but little 
is known about BGT-1 expression at the protein level, or whether increased BGT-1 
is associated with increased betaine transport. It is also not known whether betaine 
could induce the expression of BGT-1. This study further explored the possible 
changes in betaine transporter expression and function in astrocytes, after treatment 
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with high concentrations of betaine or sucrose in vitro, as well as the effect of 
betaine on its transporter BGT-1 in reactive astrocytes in vivo. Treatment of human 
U373 MG astrocytoma cells for 12 hours with 1-100 mM of betaine, but not 
equivalent concentrations of sucrose, resulted in increased BGT-1 immunointensity 
by ELISA. The increased BGT-1 was present in the cytoplasm and cell membrane. 
Treatment of cells with 1-100mM betaine also resulted in increased [14C] betaine 
transport into the cells, consistent with increased BGT-1 transporter function. No 
increase in betaine uptake was observed when cells were treated with 1 and 10 mM 
sucrose, but a large increase was observed when cells were treated with 100 mM 
sucrose. In contrast to rats received intracerebroventricular injection with kainate 
plus saline, which showed loss of BGT-1 immunoreactivity in neurons and little 
induction of BGT-1 in astrocytes, a marked increase in BGT-1 immunoreactivity 
was observed in astrocytes in the degenerating CA fields and fimbria, in rats injected 
with kainate and betaine. These astrocytes were found to have swollen mitochondria 
at electron microscopy. In view of the above findings, it is postulated that the release 
of betaine from dying neurons may be a factor in contributing to increase BGT-1 
expression in astrocytes. This might contribute to astrocytic swelling following head 
injury or stroke.    
       In summary, the present study has revealed the distribution of betaine/GABA 
transporter BGT-1 in normal brain and in excitotoxic brain injury, as well as the 
expression and functional changes of BGT-1 in astrocytes in response to 
hyperosmolarity in vitro and in vivo. Overall, the present study has dissected the role 
of BGT-1 in osmoregulation in the brain. Further studies are necessary to study the 
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mechanism by which betaine could induce BGT-1 expression and the effects of 
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Table 1. Effect of betaine / sucrose on BGT-1 expression by cell-ELISA. U373 MG 
cells were incubated for 12 hours with 1mM, 10 mM and 100 mM of betaine or 
sucrose, and BGT-1 immuno-intensity assayed by cell-ELISA. Betaine, but not 
sucrose induced increases in BGT-1 immunointensity. Values indicate means and 
SEM. n = 4 in each group. Statistically significant comparisons by one-way 
ANOVA and Bonferroni’s multiple comparison post-hoc test are as follows: a vs c 
(p<0.01), b vs c (p<0.05). Statistically significant comparisons by Student’s t-test 
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BGT-1 staining        
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Table 2. Effect of betaine / sucrose on [14C] betaine transport. U373 MG cells were 
incubated for 12 hours with 1mM, 10 mM and 100 mM of betaine or sucrose, and 
betaine uptake assayed by measuring the amount of [14C] betaine taken up into the 
cells during a 30 min incubation time intervals with [14C] betaine. An increase in 
betaine uptake was observed when cells were incubated with betaine at 1mM, 10mM 
and 100mM concentrations, and sucrose at 100mM concentrations. Values indicate 
means and SEM. n = 4 in each group. Statistically significant comparisons by one-
way ANOVA and Bonferroni’s multiple comparison post-hoc test are as follows: a 
vs c (p<0.05), d vs f (p<0.01), e vs f (p<0.01). Statistically significant comparisons 
by Student’s t-test are as follows: a vs c,d,e (P<0.05), b vs d,e (P< 0.05), c vs d,e 
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Table 3. Effect of betaine on BGT-1 expression in vivo. Rats were injected with 
kainate plus saline or kainate plus betaine, and the number of BGT-1 
immunopositive glial cells in the degenerating field CA3 or fimbria counted. 
Markedly increased numbers of BGT-1 positive glial cells were observed in rats that 
had received kainate plus betaine, compared to kainate plus saline. Numbers indicate 
mean and standard error of BGT-1 positive astrocytes per square millimeter. 
Analyzed by Student's t-test. n = 4 in each group. Significant comparisons are as 
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254.2 ± 18.5 
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1287.5 ± 24.9 
 





















Fig. 1. Schematic diagram depicting the metabolism of betaine. Choline is oxidized 
by choline dehydrogenase to betaine aldehyde, which is further oxidized to betaine 
by betaine aldehyde dehydrogenase. Betaine donates a methyl group to 
homocysteine to form methionine and dimethylglycine, a reaction catalyzed by 
betaine homocysteine methyltransferase. (The diagram is referred to ‘Garcia-Perez 
A, Burg MB (1991) Renal medullary organic osmolytes. Physiol Rev 71: 1081-
1115.’) 
 



















Fig. 2. Illustration of the metabolism of GABA. GABA is synthesized from 
glutamate by GAD67/GAD65 in GABAergic neurons. The synaptically released 
GABA is up-taken via GABA transporters into axon terminals of GABAergic 
neurons and surrounding glial cells, where GABA undergoes degradation by 
mitochondrial enzyme GABA-T. The produced glutamine in glial cells is exported 
to neurons and converted to glutamate. (The illustration is referred to ‘Farrant M 
(2002) Amino Acids: Inhibitory. In: Neurotransmitters, Drugs and Brain Function 





























Fig. 3. Western immunoblot analysis of homogenates of the monkey liver and 
cerebral neocortex.  The antibody to BGT-1 detects a major band at approximately 
60 kDa in the monkey liver (left panel), but two bands at 60 and 65kDa in 
homogenates of the monkey cortex (right panel). The higher molecular weight band 
























Fig. 4. Light micrographs of BGT-1 labelled neurons in the monkey middle 
temporal cortex (A, B) and hippocampus (C, D). A: immunoperoxidase labelled 
section through layer III (indicated) of the middle temporal cortex, showing light 
BGT-1 labelling of pyramidal neurons (arrows). B: immunoperoxidase labelled 
section through layers V and VI (indicated) of the middle temporal cortex, showing 
light labelling of pyramidal neurons (arrows). C: immunogold labelled section of 
field CA1 (indicated) of the hippocampus, showing labelling of pyramidal neuronal 
cell bodies and dendrites (arrows). D: immunogold labelled section of field CA3 
(indicated) of the hippocampus, showing staining of pyramidal neuronal dendrites 
(arrows). No staining is observed in mossy fibers of dentate granule neurons, in the 












Fig. 5. Electron micrographs of BGT-1 immunoperoxidase labelled sections through 
CA fields of the hippocampus (A) and layer V of the middle temporal cortex (B). A: 
pyramidal neuron (N), showing scattered BGT-1 label in the cytoplasm (arrows). B: 
synapses (S) between unlabelled axon terminals (AT), and a labelled dendrite (D). 
BGT-1 label (arrows) is present in the cytosol of the dendrite and in the ‘extra-
perisynaptic region’ i.e. on the cell membrane adjacent to the synapses. Scale: A = 2 












Fig. 6. Electron micrographs of BGT-1 immunogold labelled sections through CA 
fields of the hippocampus. A: pyramidal neuron (N), showing scattered BGT-1 label 
in the cytoplasm (arrows). B, C: synapses (S) between unlabelled axon terminals 
(AT), and labelled dendrites (D). BGT-1 label (arrows) is present in the cytosol of 











Fig.7. Western blot analysis of BGT-1. The antibody against BGT-1 recognizes a 
major band at approximately 60 kDa, a result consistent with the findings of Ruiz-
Tachiquin et al. (Ruiz-Tachiquin et al., 2002), in the rat liver (L), but a 60 kDa and a 
65 kDa band in both normal (N), and 1 week post kainate-injected (K) rat 
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Fig. 8. Light micrographs of sections of hippocampal field CA3 from a normal rat. A: 
GAT-1 label is absent from neuronal cell bodies, but present as a network of fibers 
in the neuropil (asterisk). B: Very little or no labelling for GAT-2 is observed 
(asterisk). C: GAT-3 staining is present in occasional glial cell bodies (arrows), but 
in large numbers of processes in the neuropil (asterisk). D: BGT-1 labelling is 
present as diffuse staining in the cell bodies of pyramidal neurons in the stratum 
pyramidale (arrows), and in the neuropil (asterisk). SO, stratum oriens; SP, stratum 






















Fig. 9. Adjacent sections of field CA3, from a rat that had been injected with kainate 
3 days earlier. A: Nissl stained section, showing loss of pyramidal neurons (arrows). 
B: GAT-1 immunostained section showing a slight decrease in immunostaining in 
the neuropil (asterisk; compare to Fig. 8A). C: GAT-3 immunostained section 
showing decreased immunoreactivity in the affected CA field (asterisk; compare to 
Fig. 8C). D: BGT-1 immunostained section, showing decreased staining in 
pyramidal neurons, but increased staining in glial cells (arrows), in the lesioned CA 




















Fig. 10. Adjacent sections of field CA3, from a rat that had been injected with 
kainate 1 week earlier. A: Nissl stained section, showing loss of pyramidal neurons 
(arrow), but large numbers of glial cells in the area affected by the kainate injection 
(asterisk). B: GAT-1 immunostained section showing decreased immunostaining in 
the neuropil, compared to untreated rats (asterisk; compare to Fig. 8A). C: GAT-3 
immunostained section showing decreased immunoreactivity in the affected CA 
field (asterisk; compare to Fig. 8C). D: BGT-1 immunostained section, showing 
markedly increased staining in astrocytes, in the lesioned CA fields (arrows). 




















Fig. 11. A, B: Adjacent sections of field CA3, from a rat that had been injected with 
kainate 3 weeks earlier. A: GAT-3 immunostained section showing decreased 
immunoreactivity in the affected CA field (asterisk; compare to Fig. 8C). B: BGT-1 
immunostained section, showing very little staining in glial cell bodies or the 
neuropil (asterisk), compared to 1-week post-kainate injected hippocampus 
(compare to Fig. 10D). C: Electron micrograph of BGT-1 immunolabelled astrocytic 
cell body in field CA3, from a rat which had been injected with kainate 1 week 
earlier. The immunopositive cells contain dense bundles of glial filaments (F) and 
are identified as astrocytes. Arrows indicate immunoreactive reaction product. N: 


















Fig. 12. Number of BGT-1 positive astrocytes in lesioned hippocampal CA3 field of 
saline-injected and kainate-injected rats. A significant increase in the number of 
BGT-1 positive astrocytes is observed in the 1-week post-kainate injected 
hippocampus, compared to the 3-day post-kainate injected hippocampus. The 
number of BGT-1 positive astrocytes declined after 1 week, and significantly fewer 
BGT-1 positive astrocytes were observed in the 3-week post-kainate injected 
hippocampus compared to the 1-week post-kainate injected hippocampus. Results 
were analyzed by 1-way ANOVA with Bonferroni’s multiple comparison post-hoc 
test. Asterisks indicate statistically significant difference, P < 0.05. (Saline: pooled 
data from rats injected with saline 3 days, 1 week and 3 weeks earlier, two rats at 
each stage. 4 kainate-injected rats are studied at each postinjection interval. 3DK: 
rats injected with kainate 3 days earlier; 1WK: rats injected with kainate 1 week 



























































Fig. 13. Double immunofluorescence labelling for BGT-1 and GFAP. A, B, C: The 
same field from a normal, untreated rat. A: Red channel, showing BGT-1 labelling 
in the stratum pyramidale (SP, asterisk). B: Green channel showing GFAP 
immunoreactivity. C: Merged channel showing few BGT-1 positive astrocytes. 
Arrow indicates a labelled glial cell. D, E, F: The same field from a rat that had been 
injected with kainate 1 week earlier. D: Red channel showing loss of neuronal 
labelling in the stratum pyramidale (asterisk; compare to A), but an increase in 
number of BGT-1 positive glial cells (arrows). E: Green channel showing GFAP 
positive astrocytes. In contrast to normal astrocytes, which have fine processes 
branching from the main cellular processes (B), these reactive astrocytes show 
hypertrophic processes. F: Merged channel showing all the glial cells in D are 





Fig. 14. RT-PCR analysis for the BGT-1 mRNA expression of human U373 MG 
astrocytoma cells. Lane 1: DNA marker. Lane 2:  A sharp band, corresponding to 
439 bp, is clearly visible in agarose gel. The band was cut and inserted into plasmid 
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Fig. 15. Effect of betaine or sucrose on BGT-1 immunoreactivity. U373 MG cells 
were incubated for 12 hours with 1mM, 10 mM and 100 mM of betaine or sucrose, 
and BGT-1 immunoreactive cells examined using a confocal microscope. A: 
Negative control in which the primary antibody BGT-1 is omitted. There is absence 
of red signal, and only the blue nuclear stain (DAPI) is visible. B: Cells incubated 
with control medium without added betaine or sucrose, showing very low level of 
BGT-1 immunoreactivity (red fluorescence) in the cytoplasm. C, D, E: Cells 
incubated with media containing 1mM, 10mM and 100mM betaine respectively, 
showing a dose-dependent increase in BGT-1 immunoreactivity (red fluorescence, 
indicated by arrows). Label is mostly present in organelles in the cytoplasm, 
although some immunoreactivity is visible on the cell membrane (arrow in E). F, G, 
H: Cells incubated with media containing 1mM, 10mM, 100mM sucrose 
respectively. There is no obvious increase in immunoreactivity of BGT-1, compared 








Fig. 16. Effect of betaine on BGT-1 expression in vivo. A: section through the 
untreated hippocampus showing light BGT-1 immunolabeling in pyramidal neurons 
(arrows) and in the neuropil (asterisk). B: BGT-1 immunolabeled section of field 
CA3, from a rat that had been injected with kainate and saline, showing loss of 
BGT-1 immunoreactivity in pyramidal neurons (asterisk), and little induction of 
BGT-1 immunoreactivity in glial cells. C: BGT-1 immunolabeled section of the 
fimbria from a rat that had been injected with kainate and saline, showing only a few 
BGT-1 immunoreactive glial cells (arrows). D: Nissl stained section from field CA3 
from a rat that had been injected with kainate and betaine, showing loss of pyramidal 
neurons (asterisk). E: BGT-1 immunolabeled section of field CA3 from the same 
animal as D, showing marked induction of immunoreactivity in glial cells (arrows). 
F: BGT-1 immunolabeled section of the fimbria from the same animal as D, 
showing marked induction of immunoreactivity in glial cells (arrows). 
Abbreviations: CTRL: uninjected control rats. KA: kainate; S: saline; B: betaine. 
















Fig. 17. Double immunofluorescence labeling for BGT-1 and GFAP from sections 
of the hippocampal CA3 field and its adjacent fimbria on the side ipsilateral to drug 
injections. A, B, C: Rats injected with kainate plus saline A: Red channel showing 
BGT-1 labeling in the stratum pyramidale. B: Green channel showing GFAP 
immunostaining. C: Merged channel showing BGT-1 labelled astrocytes. Arrow 
indicates a labeled astrocyte. D, E, F: Rats injected with kainate plus betaine D: Red 
channel showing BGT-1 immunoreactivity. There is a marked increase in number of 
labeled glial cells (arrows) in the degenerating CA3 fields and the fimbria. E: Green 
channel showing GFAP immunostaining. F: Merged channel showing that almost all 
the glial cells in Fig. D are double labeled with GFAP (arrows), indicating that they 






Fig. 18. A, B Electron micrographs of BGT-1 immunolabeled astrocytes in CA3 
field in rats that had been injected with kainate and saline. The cytoplasm contains 
dense bundles of glial filaments (F). The mitochondria (arrows) appear intact and 
normal. C, D Electron micrographs of BGT-1 immunolabeled astrocytes in rats that 
received kainate and betaine injections. The cytoplasm contains large numbers of 
swollen mitochondria (arrows). Arrowheads indicate immunoreactive reaction 
product. AS: astrocyte. Scale: 1 µm. 
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